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1Abstract
In December 2004, the Food & Drug Administration rejected Intrinsa, a testosterone transdermal system
for the treatment of hypoactive sexual desire disorder in surgically menopausal women. Intrinsa, as well
as the FDA’s decision, sparked considerable controversy. Principally, it raised questions about the use of
testosterone to treat sexual dysfunction in women. This paper examines the relationship between testosterone
and female sexual dysfunction and explores, speciﬁcally, whether there is a causal relationship between
depressed testosterone levels and sexual problems in women. It discusses normal female sexual response and
female sexual dysfunction as well as the association between testosterone and sexual diﬃculties in normal
and surgically menopausal women. Ultimately, this paper concludes that there is little evidence for a causal
relationship between low levels of testosterone and sexual dysfunction in normal women, but that depressed
testosterone levels may be associated with sexual problems in surgically menopausal women. Though Intrinsa
was purportedly created for use in surgically menopausal women, its oﬀ-label use by normal women was
probable. Facing this widespread use by women unlikely to be helped by testosterone and subject to its
unknown adverse side eﬀects, the FDA appropriately requested more safety data before approving Intrinsa.
In December 2004, the Food & Drug Administration rejected Intrinsa, a testosterone transdermal system
for the treatment of hypoactive sexual desire disorder in surgically menopausal women. Intrinsa, as well as
the FDA’s decision, sparked considerable controversy. Many sexual health researchers argued that Intrinsa
was not an appropriate treatment for female sexual dysfunction, but was, instead, the result of the pharma-
ceutical industry’s eﬀorts to create a disease for ﬁnancial gain. Others believed that Intrinsa should have
been approved and that the FDA’s grounds for rejection were improper. The debate surrounding Intrinsa
heightened awareness of women’s sexuality and sexual diﬃculties. It also raised questions about female
2sexual dysfunction and testosterone. Speciﬁcally, given testosterone’s association with maleness, why was it
being used to treat sexual problems in women?
This paper seeks to understand the relationship between testosterone and female sexual dysfunction. It
explores whether there is a causal relationship between depressed testosterone levels and sexual problems in
women and whether testosterone is an appropriate treatment for women’s sexual diﬃculties. The discussion
is divided into three parts. The ﬁrst part explores normal sexual function and sexual dysfunction in women.
It details several models of normal human sexual response as well as the physiological mechanisms underlying
this response. It then discusses female sexual dysfunction: how it is deﬁned, its prevalence and presentation
in women, and its causes. The second part of the paper focuses on testosterone. It examines the association
between testosterone levels and sexual functioning in women, and it inquires into whether women actually
suﬀer from low levels of testosterone. It concludes with a study of testosterone and sexual dysfunction in
surgically menopausal women. The third, and ﬁnal, section evaluates Intrinsa and the FDA’s decision in
light of the prior sections of this paper. It speciﬁcally addresses whether testosterone should be used to treat
women’s sexual problems.
As will become clear, there is little evidence for a causal relationship between testosterone and sexual dysfunc-
tion in the majority of women. In normal women, the data on the association between depressed testosterone
levels and sexual problems are sparse, and there appear to be few instances in which women exhibit low
testosterone concentrations. The data suggest, however, that surgically menopausal women—women who
have had their ovaries removed—experience decreases in testosterone levels. For this small group of women,
testosterone may be implicated in sexual dysfunction and may be an appropriate treatment. Though In-
trinsa was purportedly created for use in these women, its oﬀ-label use by normal women was probable. The
FDA thus faced widespread use of Intrinsa by women unlikely to be helped by the drug and subject to its
unknown adverse side eﬀects. In light of these circumstances, the FDA’s request for more safety data before
3approving Intrinsa was an appropriate, cautious response.
Normal Sexual Functioning
Our understanding of sexual health—of what is normal sexual behavior and response—is shaped by political,
social, and historical factors and has evolved over time.1 The prevailing deﬁnition of sexual health, put forth
by the World Health Organization, is as follows:
[A] state of physical, emotional, mental and social well-being related to sexuality; it
is not merely the absence of disease, dysfunction or inﬁrmity. Sexual health requires
a positive and respectful approach to sexuality and sexual relationships, as well as
the possibility of having pleasurable and safe sexual experiences, free of coercion,
discrimination and violence. For sexual health to be attained and maintained, the
sexual rights of all persons must be respected, protected and fulﬁlled.2
Central to this deﬁnition is the notion that sexual health is not just a physical condition but a state of total
corporeal, psychological, and social wellbeing.3 The right to sexual health includes negative and positive
entitlements: with respect to the former, it includes the right to be free from fear, shame, guilt, false beliefs,
and other psychological factors inhibiting sexual response and impairing sexual relationships; it includes the
right to be free from organic disorders, diseases, and deﬁciencies that interfere with sexual and reproductive
functions.4 Sexual health also implies aﬃrmative rights: it refers to the capacity to enjoy and control sexual
and reproductive behavior in accordance with social and personal ethics as well as to beneﬁt from access to
information and services.5
1Weston M. Edwards et al., Deﬁning Sexual Health: A Descriptive Overview, 33(3) Archives of Sexual Behavior 189,
189 (2004).
3Id.
4Id. at 191.
5Id.
4Many scholars argue that sexual health is not a scientiﬁc concept and thus cannot be deﬁned. Rather, what
we view as normal and healthy sexuality reﬂects cultural mores and values and changes “with the ebb and
ﬂow of time, culture, residence... sexual preference, social class, religious background, relationship status,
and ethnic background.”6 Any normative deﬁnition of sexual health fails to account for this ﬂuidity and
relativity and results in ethnocentric labels of “healthy” and “unhealthy.”7
With these concerns in mind, researchers have still attempted to decipher and to describe normal sexual
response in men and women. The driving force behind these eﬀorts has been the recognition that, to
determine what’s abnormal, we must have an understanding of what is normal. Accordingly, we begin with
a review of several models of human sexual response, paying particular attention to Masters & Johnson’s
framework,8 that purport to describe normal sexual functioning. We then consider the physiological processes
associated with female sexual response before moving onto a discussion of sexual dysfunction in women.
Models of Sexual Response
Masters & Johnson were the ﬁrst researchers to observe, describe, and ultimately deﬁne the gross physical
changes in men and women as they engaged in sexual activity.9 They sought to address the question: what
physical reactions develop as the human male and female respond to eﬀective sexual stimulation?10 Though
conducted in the early 1950’s, their research remains the seminal exploration of human sexual response.
6Id. at 192.
7Id.
8William H. Masters & Virginia E. Johnson, Human Sexual Response 4 (1966).
9Id.
10Id.
5To devise a universal model of human sexual response, Masters & Johnson studied and recorded the anatomic
and physiologic responses of 382 women (aged 18 to 78) and 312 men (aged 21 to 89) to sexual stimulation
in their reproductive biology laboratory.11 As a result of their work, they developed a four-phase model
of sexual response, with the four stages being excitement, plateau, orgasm, and resolution.12 The physi-
ologic changes women experience during each of these phases is as follows. During the excitement phase,
physical and/or psychological stimulation produces physical changes: the uterus elevates, vaginal lubrication
begins to appear, the clitoris engorges with blood, and both the labia majora and labia minora swell.13 The
breasts enlarge slightly, the nipples may become erect, and muscular contracts may occur with increasing
frequency.14 During the late excitement, or plateau, phase, sexual tension appears to level oﬀ. The uterus
elevates further (a process called “tenting”), the outer third of the vagina swells to form what is known as an
orgasmic platform, the clitoris withdraws under the clitoral hood, and the color of the labia deepens.15 The
areola begin to swell, and a reddish, spotty skin color change (“sex ﬂush”) may develop in the skin around
the upper abdomen.16 During the third phase, the orgasm phase, sexual tension peaks and discharges, with
the uterus, vagina, and rectal sphincter contracting.17 During the last phase, or resolution, the body returns
to its unaroused state.18 The uterus lowers, the orgasmic platform disappears, the vagina returns to normal,
and the clitoris returns to its unaroused position.19
Masters & Johnson’s model remains the dominant and most widely used depiction of human sexual response.
However, their model is not without ﬂaws, and it has been widely critiqued. A central criticism is that the
model concentrates on the biological aspects of sexual response at the expense of aﬀective aspects.20 The
11Id. at 13.
12Id. at 3-8.
13Id. at 69-75.
14William H. Masters, Virginia E. Johnson, & Robert C. Kolodny, Human Sexuality 76 (5th ed. 1995).
15Masters & Johnson, supra note 8, at 75-77.
16Masters et al., supra note 14, at 79.
17Masters & Johnson, supra note 8, at 77-78.
18Id. at 78-80.
19Id.
20Bryan Strong et al., Human Sexuality: Diversity in Contemporary America 98 (5th ed. 2005).
6model does not consider, for example, forces that drive women to engage in sexual activity, such as desire and
intimacy.21 Even more, in focusing on physiological changes, the model fails to examine the body as a whole,
but looks only at various body parts that move in and out of focus as the response sequence progresses.22 A
second central criticism is that the model is unduly focused on orgasm as an end point, when many women
neither orgasm nor expect to orgasm during intercourse.23
Tiefer, a particularly vociferous critic of the model, also criticizes Masters & Johnson’s presumptions,
methodology, and default treatment of men’s experiences.24 First, she argues that Masters & Johnson’s
work was a self-fulﬁlling prophecy and that their research aims biased their results.25 Wanting to describe
the “overall sexual cycle,” Masters & Johnson assumed that sexual response is an orderly, cyclic sequence
of events that does not vary from person to person.26 In keeping with their presumptions of order and
uniformity, Masters & Johnson failed to include components of sexual response that have been shown to
vary, namely initiating variables like libido, desire, and passion.27 By omitting factors that are variable and
hard to measure, Masters & Johnson increased the likelihood that they would, in fact, ﬁnd a sequential and
uniform model of sexual response.28
Secondly, Masters & Johnson’s subjects were hardly representative of the general population.29 Their pi-
lot subjects were prostitutes,30 and, for their central study, they weighted their subjects toward “higher
than average intelligence levels and socioeconomic backgrounds.”31 Though Masters & Johnson did not
appear troubled by their subject selection, it can hardly be asserted that prostitutes’ sexual experiences are
21Rosemary Basson, The Female Sexual Response Revisited, 22(5) J. Soc’y Obstetrics & Gynecology Can. 378, 379
(2000).
22Leonore Tiefer, Historical, Scientiﬁc, Clinical and Feminist Criticisms of “The Human Sexual Response Cycle” Model, 2
Annual Review of Sex Research 1, 18 (1992).
23Strong et al., supra note 20, at 105.
24Tiefer, supra note 22, at 2.
25Id. at 5.
26Id. at 2-3.
27Id. at 4.
28Id.
29Id. at 5.
30Masters & Johnson, supra note 8, at 10.
31Id. at 12.
7typical. Furthermore, it has been shown that sexual behavior does vary among women with diﬀerent educa-
tional attainment.32 Additionally, Masters & Johnson required that each subject have “a positive history of
masturbatory and coital orgasmic experience before... [being] accepted into the program.”33 Tiefer writes,
This requirement would seem to invalidate any notion that the [human sexual re-
sponse cycle] is universal. Rather, it indicates that the Masters & Johnson re-
search was designed to identify physiological functions of subjects experienced with
particular preselected sexual responses. That is, rather than the [human sexual
response cycle] being the best-ﬁt model chosen to accommodate the results of the
their research, the [model] actually guided the selection of subjects for the research...
[T]here are many sexually active and sexually responsive men and women who do
not regularly experience orgasm during masturbation and/or coitus whose patterns
of physiological arousal and subjective pleasure were deliberately excluded from the
sample. No research was undertaken to investigate “human” sexual physiology and
subjectivity, only to measure the responses of an easily orgasmic sample.34
Essentially, Masters & Johnson chose subjects well versed in communicating about sexual activity and in
achieving orgasm. As Tiefer writes, the selection of subjects precluded an examination of general human
sexual response; what Masters & Johnson examined was the trajectory of sexual response that ultimately
led to orgasm. However, not all humans are inclined towards sexual communication or orgasm and, as a
result, the human sexual response cycle cannot be said to be universal.
Finally, Tiefer criticizes Masters & Johnson’s model for depicting and thereby favoring men’s sexual interests
over those of women.35 Speciﬁcally, with its focus on genitals—vaginal intercourse and masturbation—the
model ignores women’s sexual socialization and preferences.36 For most of history, women have been sub-
ordinated socioeconomically and have lived under threat of pregnancy, male violence, and society’s double
standards.37 As a result, they have been socialized against sexual assertiveness and candor and have been
32Edward O. Laumann, Anthony Paik, & Raymond C. Rosen, Sexual Dysfunction in the United States: Prevalence and
Predictors, 281(6) JAMA 537, 540 (1999).
33Masters & Johnson, supra note 8, at 311.
35Id. at 18.
36Id.
37Id. at 19. By double standards, Tiefer refers to the traditional belief that it is socially acceptable for men to behave
promiscuously but socially unacceptable for women to do the same.
8raised to prefer intimacy and emotional communication to varied sexual experience and physical satis-
faction.38 In focusing on genital stimulation and response, however, Masters & Johnson’s model ignores
women’s social reality and sexual training, and it ultimately becomes a model that details men’s experiences
and preferences.
Researchers have responded to these critiques by formulating models of sexual response that expand upon
or diverge entirely from Masters & Johnson’s model. Three well-known alternatives to Masters & Johnson’s
model—Kaplan’s, Loulan’s, and Basson’s models of sexual response—are as follows. Kaplan’s model altered
Masters & Johnson’s work to bring in an element of psychological willingness.39 Kaplan created a tri-phasic
model of sexual response, with desire, excitement, and orgasm phases.40 She added the desire phase to the
beginning of the sexual response process; she collapsed Masters & Johnson’s excitement and plateau phases
into one excitement phase; she retained the orgasm phase; and she eliminated the resolution phase.41 During
the desire phase, individuals experience some form of thought, fantasy, or erotic feeling that causes them
to seek sexual gratiﬁcation.42 During Kaplan’s excitement phase, individuals experience the physiological
changes detailed in Masters & Johnson’s excitement and plateau phases.43 Finally, during Kaplan’s orgasm
phase, individuals experience the changes in Masters & Johnson’s orgasm phase.44
Loulan’s model, like Kaplan’s, attempts to incorporate biological and aﬀective components of sexual re-
sponse.45 The stages of her model are as follows: willingness, desire, excitement, engorgement, orgasm, and
pleasure.46 During the ﬁrst stage, willingness, two individuals consciously decide to engage in sex, even if
38Id. at 18-19.
39Strong et al., supra note 20, at 98.
40Id.
41Id.
42Id. at 100.
43Id.
44Id.
45Id.
46Id.
9there is a lack of physical or emotional desire.47 The second stage, desire, is identical to Kaplan’s desire
phase, and the third, fourth, and ﬁfth phases—the excitement, engorgement, and orgasm phases—are iden-
tical to Masters & Johnson’s excitement, plateau, and orgasm phases, respectively.48 During the ﬁnal phase,
the pleasure phase, the body returns to its unaroused state.49 Pleasure, which Loulan states is the purpose
of sexuality, can be deﬁned only by each individual and can be experienced during any and all of the prior
phases.50
Finally, Basson’s model of female sexual response considers female sexual response in the context of a long-
term relationship.51 She describes a continuous cycle, rather than a model with discrete phases. From a
state of sexual neutrality, women begin to sense the opportunity to be sexual.52 Though women may initiate
or agree to engage in sexual activity for a variety of reasons (such as anticipation of physical and emotional
pleasure), Basson theorizes that they do so primarily as a means of enhancing intimacy with their partners.53
As women begin to seek out and to be receptive to sexual stimuli, they may begin to experience sexual desire
and arousal.54 These sexual sensations then drive women to continue engaging in sexual activity, though
they may have initially instigated or agreed to sexual activity for intimacy reasons.55 As the sexual encounter
draws to an end, women may experience positive physical and/or emotional feelings, which in turn enhance
their feelings of intimacy, aﬀection, and commitment towards their partners.56 These feelings feed back into
the cycle and once again drive women to seek out or agree to sexual activity.57
Though Masters & Johnson’s model of human sexual response remains the dominant depiction of normal
47Id.
48Id.
49Id.
50Id.
51Basson, supra note 21, at 379.
52Id.
53Id.
54Id. at 380.
55Id.
56Id.
57Id.
10sexual behavior and response, much can be learned from the other models. Whereas Masters & Johnson
describe physical responses on the path to orgasm, the other models consider the psychological, emotional,
and relational factors that drive individuals to seek out sexual activity in the ﬁrst place. In addition, Loulan
and Basson’s models consider endpoints of sexual activity that are neither physical pleasure nor orgasm.
Rather, their cycles remind us that there are emotional and relational beneﬁts to engaging in sexual activity
and that many individuals do not achieve orgasm or expect to when engaging in intercourse.
Physiology of Sexual Response
Having examined models of human sexual response, we now review brieﬂy the complex interactions in
the body that result in these sexual responses as individuals engage in sexual activity. Generally, sexual
arousal and response involve the brain, speciﬁcally the cerebral cortex and limbic systems, as well as the
nervous system, the circulatory system, the endocrine glands, and the genitals.58 Sensory stimulation,
thoughts and feelings (such as expectations, fantasies, hopes, and fears), and relational and cultural inﬂuences
combine to bring individuals to a point at which they are able and willing to engage in sexual activity.59
In the brain, these inputs activate the central nervous system, particularly the medial preoptic, anterior
hypothalamic region, and related limbic hippocampal structures.60 These structures, in turn, transmit
electrical signals through the parasympathetic and sympathetic nervous systems that result in the relaxation
of vaginal and clitoral smooth muscles and increased genital blood ﬂow.61 Speciﬁcally, these vasocongestive
58Strong et al., supra note 20, at 100-103.
59Id. at 100-101.
60J.R. Berman, Physiology of Female Sexual Function and Dysfunction, 17 Int’l. J. Impotence Res. S44, S46 (2005).
61J.R. Berman et al., Clinical Evaluation of Female Sexual Function: Eﬀects of Age and Estrogen Status on Subjective and
Physiologic Sexual Responses, 11 Int’l J. Impotence Res. (Supp. 1) S31, S31 (1999).
11and neuromuscular events culminate in increased clitoral and vaginal length and diameter as well as increased
vaginal lubrication and wall engorgement.62 Hormones, such as estrogen, testosterone, and oxytocin, are
thought to contribute to these changes. Estrogen, for example, aﬀects cells throughout the peripheral and
central nervous systems and inﬂuences nerve transmission.63 It also has
vaso-protective and vasodilatory eﬀects, which result in increased vaginal, clitoral, and urethral arterial blood
ﬂow.64
We have thus far reviewed the physiological and aﬀective changes associated with sexual response as well as
the underlying biological mechanisms that result in these changes. With a sense of what constitutes normal
sexual functioning, we now consider sexual dysfunction.
Female Sexual Dysfunction
The distinction between normal and abnormal sexual functioning is not always clear.65 Cultural norms
diﬀer, as do individual perceptions of what is healthy and what is problematic sexual behavior and response.
Furthermore, levels of sexual desire and forms of sexual activity vary enormously in any given population,
and these diﬀerences do not inevitably imply sexual dysfunction.66 Unsurprisingly, there has been great
debate among researchers about how to describe and classify sexual diﬃculties.
62Id.
63Berman, supra note 60, at S46.
64Id. at S47.
65Strong et al., supra note 20, at 488.
66Id.
12In this section, we begin with a review of three classiﬁcation systems used to deﬁne female sexual dysfunction.
First, we discuss the American Psychiatric Association’s classiﬁcation system, found in the Diagnostic and
Statistical Manual of Mental Disorders (the “DSM-IV”), which is currently the standard medical diagnostic
classiﬁcation system.67 We then consider the system proposed by a recent Consensus Development Panel
(the “consensus panel”) on female sexual dysfunction.68 Thirdly, we review the framework proposed by the
Working Group for a New View of Women’s Sexual Problems (the “working group”).69 After discussing these
models, we examine research that inquires into the prevalence and patterns of female sexual dysfunction.
Finally, this section closes with a delineation of the numerous causes of sexual dysfunction in women.
Deﬁning Female Sexual Dysfunction
We begin with the DSM-IV classiﬁcation system, the most widely used categorization of sexual dysfunctions.
The DSM-IV deﬁnes sexual dysfunction as “characterized by a disturbance in the processes that characterize
the sexual response cycle or by pain associated with sexual intercourse.”70 The DSM-IV classiﬁcation is based
on a combination of Masters & Johnson and Kaplan’s models of human sexual response.71 The manual
recognizes a four-phase sexual response cycle with an appetite/desire phase, an excitement/arousal phase,
an orgasmic phase, and a resolution phase, and it classiﬁes disorders in accordance with these phases.72
67American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders IV (2000),
http://online.statref.com/document.aspx?fxid=37&docid=7.
68Rosemary Basson et al., Report of the International Consensus Development Conference on Female Sexual Dysfunction:
Deﬁnitions and Classiﬁcations, 163(3) J. Urology 888, 888 (2000).
69The Working Group on A New View of Women’s Sexual Problems, A New View of Women’s Sexual Problems, 3(15)
Electronic J. Hum. Sexuality (2000), http://www.ejhs.org/volume3/newview.htm.
70American Psychiatric Association, supra note 67.
71Id.
72Id.
13Speciﬁcally, the central sexual dysfunctions are sexual desire disorders, sexual arousal disorders, orgasmic
disorders, and sexual pain disorders.73
The sexual dysfunctions experienced by women are as follows:
Sexual desire disorders:
♣
Hypoactive sexual desire disorder: persistently or recur-
rently deﬁcient (or absent) sexual fantasies and desire for sexual activity, causing
marked distress or interpersonal diﬃculty.74
♣
Sexual aversion disorder: persistent or recurrent extreme
aversion to, and avoidance of, all (or almost all) genital sexual contact with a sexual
partner, causing marked distress or interpersonal diﬃculty.75
Sexual arousal disorder:
♣
Female sexual arousal disorder: persistent or recurrent in-
ability to attain, or to maintain until completion of the sexual activity, an adequate
lubrication-swelling response of sexual excitement, causing marked distress or in-
terpersonal diﬃculty.76
Orgasmic disorder:
♣
Female orgasmic disorder: persistent or recurrent delay in,
or absence of, orgasm following a normal sexual excitement phase, causing marked
distress or interpersonal diﬃculty.77
Sexual pain disorders:
♣
73Id.
14Dyspareunia: recurrent or persistent genital pain associ-
ated with intercourse, causing marked distress or interpersonal diﬃculty.78
♣
Vaginismus: recurrent or persistent involuntary spasms of
the musculature of the outer third of the vagina that interferes with sexual inter-
course, causing marked distress or interpersonal diﬃculty.79
In addition to these disorders, the DSM-IV includes the three categories “Sexual Dysfunction Due to a
General Medical Condition,” “Substance-Induced Sexual Dysfunction,” and “Sexual Dysfunction Not Oth-
erwise Speciﬁed.”80 The ﬁrst refers to conditions that are the direct physiological eﬀect of a general medical
condition; the second refers to conditions that develop as a result of substance-induced intoxication; and the
third refers to conditions that do not meet criteria for any speciﬁc dysfunction.81 For all categories of sexual
dysfunction, the DSM-IV speciﬁes onset (lifelong versus acquired) and contextual (generalized, occurring in
all sexual situations, versus situational) subtypes.82
Disorders of sexual desire describe problems with the ﬁrst phase of the sexual response cycle, the appetite
or desire phase. Individuals with hypoactive sexual desire disorder have inhibited or low sexual desire and
participate reluctantly in sexual activity that is initiated by a partner.83 However, because there is no
“normal” level of sexual desire—“normal” people diﬀer in their sexual fantasies and needs—deﬁning and
identifying low sexual desire is a diﬃcult and subjective task.84 Whereas hypoactive sexual desire disorder
is characterized by an absence of desire, sexual aversion disorder is characterized by an active dislike or fear
of sexual contact. Individuals respond to the possibility of sexual conduct with anxiety, disgust, or fear and,
80Id.
81Id.
82Id.
83Id. at § 302.71.
84Strong et al., supra note 20, at 496.
15in some cases, may experience physiological responses such as sweating, dizziness, or nausea.85
Women with sexual arousal disorders want sexual activity but are unable to maintain their physiological
levels of arousal. This often results in vaginal dryness or tightness that can make intercourse uncomfort-
able.86 However, it is important to note that some women experience a disconnect between physiological and
subjective arousal: they may report an absence of lubrication but may still experience sexual excitement or
they may report lubrication but may not feel aroused.87 The DSM-IV fails to consider psychological arousal
and its connection, or lack thereof, to physiological arousal.
Orgasmic disorders, like arousal disorders, implicate arousal rather than desire. Women with orgasmic dis-
order often want and enjoy sexual activity, but they are unable to climax. Orgasmic disorder is usually a
lifelong condition, because once women learn to achieve orgasm, they rarely lose that capacity.88 This cate-
gory of sexual dysfunction has been criticized because, ﬁrst, many women do not have orgasms and, second,
women vary with respect to the type and intensity of stimulation that results in orgasm.89 Speciﬁcally, 10-
15% of women report never having orgasms, and another 10-15% report rarely having them.90 Additionally,
some women achieve orgasm through manual or oral stimulation only, whereas others require intercourse.91
This considerable variation suggests that we, as a society, may unduly pathologize the inability to orgasm.
Finally, women with sexual pain disorders experience pain or vaginal muscle contractions that limit their
ability to engage in intercourse. Though most women report occasional pain during intercourse, women with
dyspareunia report persistent pain.92 In women with vaginismus, the muscles around the vagina go into
involuntary contractions, which can prevent the insertion of any object.93 Both dyspareunia and vaginismus
85American Psychiatric Association, supra note 67, at § 302.79.
86Strong et al., supra note 20, at 497-498.
87Id. at 498.
88American Psychiatric Association, supra note 67, at § 302.73.
89Strong et al., supra note 20, at 499.
90Id.
91Id.
92Id. at 502.
93American Psychiatric Association, supra note 67, at § 306.51.
16are not the result of medical or physiological conditions, but are thought to have strong psychological com-
ponents.94
The DSM-IV classiﬁcation system has been criticized for a number of reasons, many of which are similar to
the critiques of Masters & Johnson’s model of human sexual response. Researchers challenge the fact that
the classiﬁcation examines body parts in isolation and fails to consider both the body as a whole as well
as the psychological and relational contexts in which the body engages in sexual activity.95 They also ﬁnd
the DSM-IV’s focus on heterosexual intercourse and orgasm shortsighted and limiting.96 Tiefer’s critique of
Masters & Johnson’s human sexual response model highlights the fact that the DSM-IV criteria are based
on a sexual response cycle that is not necessarily universal.97
In the late 1990’s, a panel of 19 experts in female sexual dysfunction gathered to “evaluate and revise exist-
ing deﬁnitions and classiﬁcations of female sexual dysfunction.”98 They developed a “new” consensus based
classiﬁcation system that purported to include organic, as well as psychological, causes of sexual dysfunction.
In reality, however, the framework is very similar to that found in the DSM-IV. Generally, the panel retained
the four major DSM-IV categories (desire, arousal, orgasm, and pain disorders) and made some changes to
the deﬁnitions of particular disorders.99 The altered deﬁnitions are as follows, with additions to the DSM-IV
criteria in bold and deletions from the criteria crossed out.
Sexual desire disorders:
♣
94Id. at § 302.76, 306.51.
95Strong et al., supra note 20, at 489.
96Id.
97Tiefer, supra note 22, at 5-6.
98Basson et al., supra note 68, at 888.
99Id. at 890.
17Hypoactive sexual desire disorder: persistently or recur-
rently deﬁcient (or absent) sexual fantasies and desire for or receptivity to sexual
activity, causing personal distress or interpersonal diﬃculty.100
♣
Sexual aversion disorder: persistent or recurrent extreme
aversion to, and avoidance of, all (or almost all) genital sexual contact with a sexual
partner, causing marked distress or interpersonal diﬃculty.101
Sexual arousal disorder:
♣
Female sexual arousal disorder: persistent or recurrent in-
ability to attain or maintain suﬃcient sexual excitement, causing personal distress
or interpersonal diﬃculty, which may be expressed as a lack of subjective ex-
citement or genital (lubrication/swelling) or other somatic responses.102
Orgasmic disorder:
♣
Female orgasmic disorder: the persistent or recurrent diﬃ-
culty, delay in or absence of attaining orgasm following suﬃcient sexual stimulation
and arousal, which causes personal distress or interpersonal diﬃculty.103
Sexual pain disorders:
♣
Dyspareunia: recurrent or persistent genital pain associ-
ated with sexual intercourse, causing marked distress or interpersonal diﬃculty.104
♣
Vaginismus: recurrent or persistent involuntary spasm of
the musculature of the outer third of the vagina that interferes with vaginal pene-
tration, which causes personal distress or interpersonal diﬃculty.105
♣
18Noncoital sexual pain disorder: recurrent or per-
sistent genital pain induced by noncoital sexual stimulation.106
Each diagnosis is subtyped as lifelong versus acquired and generalized versus situational and is classiﬁed as
organic, psychogenic, mixed, or unknown in origin.107
Several changes are worth highlighting. The panel broadened sexual aversion disorder to refer to aversion to
all sexual contact, rather than just genital sexual contact. Similarly, sexual arousal disorder was expanded
to recognize a wide range of non-genital physical arousal (called “other somatic response”) and subjective
arousal (called “subjective excitement”) characteristic of sexual response in women. The panel also included
a new disorder, noncoital sexual pain disorder, to recognize that women may experience pain during noncoital
sexual activity. Finally, whereas the DSM-IV considers personal and interpersonal diﬃculty as hallmarks of
sexual dysfunction, the consensus panel asserted that only women’s distress, and not their partners’, would
result in a diagnosis.
Above all, the consensus panel maintains that its new classiﬁcation system diﬀers from others, namely
the DSM-IV, because it is “based on physiological as well as psychological pathophysiologies” (it suggests
that the DSM-IV is purely a psychological model).108 However, it is not apparent from the diagnostic
criteria that this physiological angle has been “added.” Even more, it’s not apparent why the panel felt the
need to add this element, because the DSM-IV does, in fact, consider physiologically-based female sexual
dysfunction. In its introduction of sexual disorders, the DSM-IV states that a sexual dysfunction may be
due to a combination of psychological and physiological factors when “psychological factors are judged to
107Id.
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19have a role in the onset, severity, exacerbation, or maintenance of the Sexual Dysfunction... and a general
medical condition or substance use is also judged to be contributory.”109 Furthermore, the DSM-IV includes
a category entitled “Sexual Dysfunction Due to a General Medical Condition.”110 The consensus panel fails
to acknowledge these points, and it appears to assert the physical causes of female sexual dysfunction for no
other reason than to assert that sexual disorders can be caused by medical conditions.
The ﬁnal classiﬁcation system we will review is entitled “A New View of Women’s Sexual Problems.”111 This
framework is considerably diﬀerent from the DSM-IV and consensus panel’s criteria, and it purports to create
a system based on women’s needs and sexual realities. In particular, these researchers sought to avoid the
three central shortcomings of other classiﬁcation systems: an assumed sexual equivalency between men and
women, a failure to acknowledge the role of relationships in sexuality, and the leveling of diﬀerences among
women.112 Furthermore, in light of the consensus panel’s eﬀorts to focus on physical causes of female sexual
dysfunction, the working group hoped to shift concentration from the physiological back to the psychosocial
causes of sexual disorders.113
The working group deﬁnes sexual problems “as discontent or dissatisfaction with any emotional, physical,
or relational aspect of sexual experience.”114 These problems are thought to arise, for the most part, out of
distress and inhibition that result from cultural and relational factors.115 The working group’s framework is
as follows:
109American Psychiatric Association, supra note 67.
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20Sexual problems due to socio-cultural, political, or economic factors:116
A.
Ignorance and anxiety due to inadequate sex education,
lack of access to health services, or other social constraints:
1.
Lack of vocabulary to describe subjective or
physical experience.
2.
Lack of information about human sexual biology
and life-stage changes.
3. Lack of information about how gender roles inﬂuence men’s and women’s sexual expectations, beliefs,
and behaviors.
4. Inadequate access to information and services for contraception and abortion, STD prevention and
treatment, sexual trauma, and domestic violence.
B.
Sexual avoidance or distress due to perceived inability to
meet cultural norms regarding correct or ideal sexuality, including:
1.
Anxiety or shame about one’s body, sexual
attractiveness, or sexual responses.
2. Confusion or shame about one’s sexual orientation or identity, or about sexual fantasies and desires.
C.
116Id.
21Inhibitions due to conﬂict between the sexual norms of
one’s subculture or culture of origin and those of the dominant culture.
D. Lack of interest, fatigue, or lack of time due to family and work obligations.
Sexual problems relating to partner and relationship:117
A.
Inhibition, avoidance, or distress arising from betrayal,
dislike, or fear of partner, partner’s abuse or couple’s unequal power, or arising
from partner’s negative patterns of communication.
B. Discrepancies in desire for sexual activity or in preferences for various sexual activities.
C. Ignorance or inhibition about communicating preferences or initiating, pacing, or shaping sexual ac-
tivities.
D. Loss of sexual interest and reciprocity as a result of conﬂicts over commonplace issues such as money,
schedules, or relatives, or resulting from traumatic experiences, e.g., infertility or the death of a child.
E. Inhibitions in arousal or spontaneity due to partner’s health status or sexual problems.
Sexual problems due to psychological factors:118
A.
Sexual aversion, mistrust, or inhibition of sexual pleasure
due to:
1.
Past experiences of physical, sexual, or emotional
abuse.
2.
General personality problems with attachment,
rejection, co-operation, or entitlement.
223. Depression or anxiety.
B.
Sexual inhibition due to fear of sexual acts or of their pos-
sible consequences, e.g., pain during intercourse, pregnancy, sexually transmitted
disease, loss of partner, loss of reputation. ?
Sexual problems due to medical factors:119
Pain or lack of physical response during sexual activity despite a supportive and safe
interpersonal situation, adequate sexual knowledge, and positive sexual attitudes. Such
problems can arise from:
A.
Numerous local or systemic medical conditions aﬀecting
neurological, neurovascular, circulatory, endocrine or other systems of the body.
B. Pregnancy, sexually transmitted diseases, or other sex-related conditions.
C. Side eﬀects of many drugs, medications, or medical treatments.
D. Iatrogenic conditions.
This model attributes sexual dysfunction largely to psychosocial concerns, rather than physical conditions,
and its inclusion of these psychosocial causes is extensive. With respect to socio-cultural factors, the model
recognizes, for example, that in some societies women may remain subordinated to men and that this sexual
inequality may result in sexual inhibition. In other societies, women might not have access to sexuality
education or health services, and they may not understand or feel comfortable with their bodies and their
sexuality. Alternatively, women’s relational concerns may be at the root of their sexual diﬃculties. Women
may be unable to communicate with their partners, may be dissatisﬁed with them, or may have diﬀerent
sexual preferences. The model also refers to psychological causes for sexual problems: women who suﬀer from
23sexual abuse, attachment disorders, or depression may have diﬃculty with their sexual lives. Finally, in some
cases, medical conditions may result in sexual dysfunction. These may include neurological or circulatory
problems as well as the side eﬀects of numerous medications.
Though the working group’s model provides insight into the social, relational, and psychological contexts in
which sexual dysfunction takes place, it is, in practice, diﬃcult to operationalize. That is, we have a sense
of what causes sexual dysfunction, but we are not told how the sexual problems manifest themselves. There
are no variables and no end points that can be examined, measured, and compared. This eﬀectively limits
research and scholarship on sexual problems.
At this point, we have reviewed three models of female sexual dysfunction, which focus to varying degrees
on physiological and psychosocial aspects of sexual concerns. We now consider the prevalence and patterns
of sexual dysfunction in women.
Prevalence and Patterns
Prevalence
In this section, we review several studies that examine the prevalence of sexual dysfunction symptoms in
women, paying particular attention to the National Health and Social Life Survey.120 We also consider a
few studies that inquire into the prevalence of sexual dysfunction in a diﬀerent way: namely, by looking into
women’s levels of distress associated with their sexuality and supposed sexual problems.
120Laumann et al., supra note 32, at 537.
24The National Health and Social Life Survey (the “NHSLS”) is the most widely cited study on the prevalence
of sexual dysfunction.121 Conducted in 1992, the NHSLS was the ﬁrst population-based assessment to
examine adult sexual behavior in the United States since Kinsey’s work. The NHSLS surveyed 1410 men
and 1749 women between the ages of 18 and 59 and living in households in the U.S.122 Each participant
was interviewed in person for approximately 90 minutes.123 Researchers examined sexual dysfunction by
inquiring into 1) lack of desire for sex, 2) arousal diﬃculties (erection problems in men and lubrication
problems in women, for example), 3) inability achieving climax, 4) anxiety about sexual performance, 5)
climaxing too early, 6) physical pain during sex, and 7) not ﬁnding sex pleasurable.124 The researchers found
the total prevalence of sexual dysfunction in women to be 43%, notably higher than the 31% prevalence in
men.125 Speciﬁcally, 22% of women surveyed were aﬀected by low sexual desire, 14% by arousal problems,
and 7% by sexual pain.126
Other studies have produced diﬀerent prevalence percentages. Goldmeier et al. asked 100 female and 103
male attendees at a genitourinary clinic whether they had experienced dissatisfaction with their sex lives or
sexual problems over the last year.127 Those who answered yes underwent a clinical interview to determine
the speciﬁcs of the problem.128 In this study, 20% of women reported sexual dysfunction.129 Of the 20%,
50% had anorgasmia, 35% had decreased sexual desire, 20% had arousal problems, and 10% were generally
dissatisﬁed with their sex lives.130 In another study, questionnaires were mailed to women at military medical
clinics.131 Of the 1584 women who responded, 98% reported one or more sexual concerns, such as lack of
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25interest, sexual aversion, and diﬃculty with orgasm and intercourse.132 The authors noted, however, that the
prevalence of sexual dysfunction might have been inﬂated because women with sexual diﬃculties might have
been more likely to send back the questionnaires.133 Indeed, the prevalence of sexual dysfunction appears
to vary considerably from study to study.
The NHSLS, as well as other typical prevalence studies, examine the prevalence of sexual dysfunction by
inquiring about the presence of clinical symptoms of the various dysfunctions. These studies, however, have
been criticized as being overinclusive because they fail to consider women’s feelings about their supposed
dysfunctions.134 In the NHSLS, for example, the presence of sexual dysfunction was based on yes/no answers
to the following questions: “During the last 12 months has there ever been a period of several months or
more when you, a) lacked interest in having sex, b) were unable to climax (experience an orgasm), c) came
to climax too quickly, d) experienced physical pain during intercourse, e) did not ﬁnd sex pleasurable (even
if it was not painful), f) felt anxious just before having sex about your ability to perform sexually, or g) had
trouble lubricating?”135 If a woman answered yes to at least one of these questions, she was seen as having
a sexual dysfunction.136 First, it is questionable that the NHSLS authors allowed the presence of a sexual
dysfunction to be based on the answer to one question. But even more, the authors did not ask whether
such “dysfunctions” had ever caused distress or were considered problematic by the women themselves.137
If a woman answered “yes” to lack of sexual interest for several months, for instance, she would be seen
as having sexual desire disorder, even if her lack of desire did not trouble her. Implicit in this criticism
283 (2004).
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26is the notion that some inhibition of sexual interest or response might be adaptive: it might occur as an
appropriate, or at least understandable, reaction to certain circumstances.138 It is therefore important to
assess women’s perceptions of their so-called sexual dysfunctions, because these perceptions are arguably
necessary to determine whether their experiences are actually problematic.
A study by Haavio-Mannila & Kontula, for example, inquired into women’s satisfaction with their sex lives
and reported considerably lower rates of sexual dissatisfaction than the NHSLS.139 Interviews with 1146
women aged 18-74 revealed that 6% of women found their sex lives unsatisfying, 13% found their sex lives
neither unsatisfying nor satisfying, 52% quite satisfying, and 29% very satisfying.140 Fewer women appeared
to have sexual problems when they were asked about their general happiness with respect to their sex lives,
rather than about the presence of clinical symptoms of sexual dysfunction.
Bancroft et al. conducted a study that examined women’s distress about their sexual experiences.141 Re-
searchers asked 987 women aged 20-65 detailed questions about their sexual experiences and responses over
the preceding month and about whether their sex lives distressed or worried them.142 Sexual distress was
assessed with the following two questions: 1) During the past 4 weeks, how much distress or worry has
your sexual relationship caused you? 2) During the past 4 weeks, how much distress or worry has your own
sexuality caused you? 143 Answers were categorized as no distress, slight distress, and marked distress.144
The authors hoped to distinguish between distress that was a reaction to problems with the partner or sexual
relationship and distress that was a reaction to concerns about the woman’s capacity for sexual response.145
The results indicated that 19.8% of women had marked distress about their relationship, and 14.7% had
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27marked distress about their own sexuality.146 In total, 24.4% of the sample had marked distress about their
sexual relationship or their own sexuality or both.147 Furthermore, 31.4% had slight distress about either
or both, and 44.2% reported no distress of either kind.148 Focusing on the 14.7% of markedly distressed
women, the authors reported that, when women’s own conceptions of their sexual “problems” are assessed,
only one-third to one-half of women operationally deﬁned as having a sexual dysfunction (satisfying diag-
nostic criteria, that is) actually regarded themselves as having a problem or reported marked distress about
the supposed problem.149
In light of Laumann et al.’s 43% prevalence statistic, these results raise several questions. With respect
to calculating the prevalence of sexual dysfunction, is the presence of symptoms—a loss of sexual desire or
an inability to climax, for example—suﬃcient to declare that a woman has a given dysfunction? Or is a
measurement of a woman’s distress about a particular sexual problem or about sexuality in general a better
indicator of the presence of sexual dysfunction? Alternatively, given that DSM-IV diagnostic criteria require
symptoms and marked distress for a diagnosis, are both elements necessary?
K. ¨ Oberg et al. examined the prevalence of sexual dysfunction symptoms (sexual dysfunction per se) as
well as the prevalence of personal distress caused by sexual dysfunction in a sample of 1056 women aged
18-65.150 Women were asked about problems with sexual desire, interest, lubrication, orgasm, genital pain,
and vaginismus and were asked to describe their dysfunction, if any, as none, mild (sporadically occurring),
or manifest (occurring often or all the time).151 Each subject was also asked to rate her distress associated
with each dysfunction as none, mild, or manifest.152
The results indicated that the prevalence of distress was generally lower than the prevalence of sexual
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28dysfunction per se.153 For example, 29% of women reported manifest decreased sexual interest, and 60%
reported mild decreased sexual interest.154 However, of the 29% with manifest decreased sexual interest,
47% had manifest personal distress, 40% had mild distress, and 13% had no distress.155 Similarly, of the 60%
with mild decreased sexual interest, 2% showed manifest distress, 54% mild distress, and 45% no distress.156
It appeared that, though women perceived themselves as suﬀering from some sort of sexual dysfunction,
they did not necessarily experience the corresponding level of personal distress. The authors suggested that,
from a clinical point of view, distress associated with sexual problems appears more relevant than sexual
dysfunction per se.157
The study also found that aggregated manifest and mild dysfunction per se of sexual interest, orgasm and
vaginal lubrication were reported by about 60-90% of the sample, with mild dysfunctions accounting for con-
siderably more of this percentage.158 With respect to this ﬁgure, they authors stated that “the prevalence
of mild dysfunction is so high that it can be contemplated whether mild dysfunction might be regarded as
‘normal’ variation and not a clinical condition. This is further underscored by the fact that no more than
1-2% of women reporting mild dysfunction experienced it as manifestly distressing.”159 This highlights,
again, the relevance of women’s feelings about their so-called sexual dysfunctions.
In summary, the most widely cited prevalence statistic for female sexual dysfunction is that reported by
the NHSLS: 43%. However, it is important to remember that this study did not take into account whether
women viewed their sexual problems as troublesome. Studies that do consider women’s perceptions of their
sexuality and sexual diﬃculties tend to suggest that one-third to one-half of women with sexual dysfunction
symptoms actually view these as problematic. Furthermore, as illuminated by K. ¨ Oberg et al., it is possible
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29that sexual diﬃculties may be so prevalent that some level of dysfunction is normal.
Patterns
We move now to a brief discussion of the relationship between sexual dysfunction and various demographic
variables. We also examine several risk factors and concomitants.
The NHSLS is, again, the seminal study on this subject. The NHSLS noted several demographic trends.
First, married women were less likely to experience sexual dysfunction than premarital (never married)
women and postmarital (divorced, widowed, or separated) women.160 That is, pre and postmarital women
were approximately 1.5 times as likely as married women to have problems climaxing and to experience sexual
anxiety.161 Second, higher educational attainment was negatively associated with sexual problems: women
who had graduated from college were half as likely to suﬀer from low sexual desire, diﬃculties achieving
orgasm, sexual pain, and sexual anxiety than women who had not graduated from high school.162 Third, the
authors reported a variable relationship between race and ethnicity and sexual dysfunction.163 Black women
reported more low sexual desire and less pleasure than did white women, but white women were more likely
to experience sexual pain than black women.164 Hispanic women reported lower rates of sexual problems in
general.165
The NHSLS also found that the prevalence of sexual problems decreased with age, with the exception
of lubrication problems, which appeared to increase with age.166 Other studies have found the opposite,
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30however. Nusbaum’s research, for example, found that, when women were divided into age groups (younger
than 44, 45-54, and 54 and older), sexual function concerns were similar across the age groups but were more
intense in older women.167
The NHSLS also examined risk factors, including health, lifestyle, social status, and sexual experience, in
relation to sexual dysfunction categories (unaﬀected, low sexual desire, arousal problems, and sexual pain).
With respect to health and lifestyle risk factors, women with emotional and stress-related problems were
more likely to report sexual dysfunctions in each category.168 In contrast, poor health was related only
to sexual pain for women.169 Social status variables—variables that measure socioeconomic status and
individuals’ normative position relative to others—showed that a decline in a woman’s economic position,
as measured by falling household income, was associated with a modest increase in risk for all categories
of sexual dysfunction.170 When measuring sexual experience, the authors found that women who reported
low sexual activity or interests had an elevated risk for low sexual desire and arousal disorders.171 Sexual
victimization, either through adult-child contact or forced sexual contact, was also highly associated with
arousal problems.172
Finally, the NHSLS studied quality-of-life concomitants and sexual concerns. It found sexual dysfunction to
be highly associated with unsatisfying personal experiences and relationships.173 Speciﬁcally, low emotional
satisfaction and low levels of happiness were strongly associated with sexual dysfunctions.174 Bancroft et
al.’s work conﬁrmed this ﬁnding: they reported that a lack of emotional wellbeing and negative emotional
feelings during sexual interactions were associated with sexual distress.175 In fact, women’s negative mental
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31states were more important determinants of sexual distress than their physiological sexual impairments.176
In sum, the central trends appear to be as follows. There is an elevated risk of sexual dysfunction with low
educational attainment and minority status—this may attest to the fact that better educated individuals
generally live healthier, less stressful lives. In a related vein, psychological disturbance appears to aﬀect
sexual functioning: emotional and stress-related problems generate an elevated risk of experiencing all forms
of sexual dysfunction. It is not clear, however, whether sexual dysfunction increases or decreases with age.
The NHSLS found sexual problems to be more common in young women. The authors noted that young
women’s inexperience and instability (high partner turnover, periods of sexual inactivity) might result in
stressful sexual encounters, which may provide the basis for sexual diﬃculties.177 Conversely, Nusbaum
found that older women were more aﬀected by sexual diﬃculties than younger women.
Causes
In this section, we review potential causes of female sexual dysfunction. This discussion is not meant to
be exhaustive, but is intended to provide an overview of the principal psychosocial and biological origins of
sexual problems.
Psychosocial Causes
Psychosocial causes of sexual dysfunction can be divided into three categories: immediate causes, conﬂict
within the self, and relationship concerns.178
176Id.
177Laumann et al., supra note 32, at 542.
178Strong et al., supra note 20, at 505-507.
32Immediate causes include fatigue and stress, ineﬀective sexual behavior, sexual anxieties, and an excessive
need to please a partner.179 To begin, weariness from the demands of every day life may result in sexual
apathy or disinterest.180 Raising children, working, and worrying about ﬁnances, for example, may leave
couples too tired to engage in sexual activity at the end of the day. Long-term stress, such as that associated
with coping with chronic illness, can also result in lowered sexual drive and reduced responsiveness.181
A lack of information and ineﬀective sexual techniques may also prevent some couples from being successful
sexually with each other. Masters & Johnson note that men and women may not know what their partners
ﬁnd arousing and/or what they themselves ﬁnd arousing.182 In particular, many couples are unaware of the
importance of the clitoris in female sexual arousal and of the need for direct stimulation.183 Alternatively,
some individuals may know what arouses them, but may be unable to communicate this information to their
partners and/or may not be aroused by the techniques their partners use.184
A number of sexual anxieties can also lead to sexual problems. Performance anxiety, for example, may cause
individuals to become obsessed with performing adequately in a sexual encounter and may lead them to
focus on their performance rather than on their own pleasure or satisfaction.185 In a study of 198 adults
with sexual dysfunction and 145 adults without sexual dysfunction, McCabe found that women with sexual
dysfunction exhibited considerably higher levels of performance anxiety than controls.186 Furthermore, a
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33multiple regression analysis identiﬁed performance anxiety as one of the central variables in predicting the
extent of sexual dysfunction in women.187
In a related vein, an excessive desire to please a partner may contribute to sexual dysfunction in women.
Darling & Davidson reported that approximately two-thirds of women pretend to have orgasms during sexual
activity with their partners.188 Women may pretend to have orgasms to avoid disappointing their partners or
to present a certain image of themselves as sexual beings.189 Ultimately, because women lead their partners
to believe that they are sexually satisﬁed, their orgasmic diﬃculties are never addressed or resolved.190
A second set of psychosocial causes of female sexual dysfunction is conﬂict within the self. It is thought
that conﬂicting feelings about sexual activity may lead to sentiments of confusion and guilt that may inhibit
sexual drive and alienate a person from her sexuality.191 Such conﬂict may arise for a number of reasons,
including negative parental, personal, or religious attitudes toward sex as well as traumatic sexual experi-
ences.192 With respect to attitudes towards sexual activity, in a study of the relationships among childhood,
adolescent, and adult factors and sexual dysfunction, McCabe & Deakin found that negative parental atti-
tudes about sex were strongly associated with sexual dysfunction in adulthood.193 Additionally, in her study
on performance anxiety and sexual dysfunction, McCabe’s multiple regression analysis determined that an
individual’s attitude toward sex, as well as her performance anxiety, predicted sexual dysfunction.194
Religious beliefs may also contribute to sexual dysfunction in women. Davidson et al.’s study of religiosity
and sexuality found, for example, that women who attended religious services frequently were more likely
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34to perceive masturbation as a sin and unhealthy practice than women who attended religious services less
frequently.195 Additionally, they were more likely to feel guilty about masturbating and to be ashamed to
admit to engaging in masturbation.196 These studies suggest that negative attitudes about sex, whether they
are derived from parental beliefs, personal feelings, or religious views, may predispose individuals toward
developing sexual dysfunctions.
Traumatic sexual experiences, including child abuse, incest, and rape, are also strongly linked to the devel-
opment of sexual dysfunction. With respect to child sexual abuse, it is thought that sexual abuse during
childhood impairs sexual development, sexual decision-making, and interpersonal functioning as well as psy-
chological and biological processes.197 This impairment, in turn, can lead to the development of sexual
diﬃculties. In a review of studies on child sex abuse, Wyatt noted that survivors of child sexual abuse
reported numerous sexual problems, such as avoidance of sex, diﬃculty in touching and caressing their part-
ners or being caressed themselves, and experiencing feelings of disgust about their own or their partner’s
body.198 Another review indicated that women with a history of child sexual abuse were more likely to
report sexual desire, arousal, and orgasm disorders, particularly if they were victimized multiple times.199
Survivors of rape and incest show similar problems. A study of sexual functioning in survivors of rape and
incest revealed markedly higher rates of sexual problems in these survivors than in controls.200 Speciﬁcally,
58.6% of the survivors had at least one sexual problem, whereas only 17.2% of nonassaulted women had a
sexual problem.201 The nature of the sexual problems also diﬀered between the two groups: survivors of sex-
ual abuse were more likely to report symptoms that would prevent them from being sexual altogether, such
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35as fear of sex, desire dysfunctions, and arousal dysfunctions.202 Nonassaulted women, however, were more
likely to report symptoms that did not diminish their desire for sex or their arousability, such as boredom
with a sexual partner and less intense orgasms.203
A third category of psychosocial causes of sexual dysfunction is relationship concerns. These may include
fears of becoming intimate with a partner, problems in a relationship, diﬀering sexual tastes, and unequal
power dynamics. To elaborate, some women may enjoy sexual activity but may fear its accompanying vul-
nerability.204 Other women and their partners may have unresolved feelings of disappointment, anger, and
hurt that come to characterize their relationship and to impair their sex lives.205 Masters & Johnson also
note that partners’ conﬂicting sex value systems or very diﬀerent sexual preferences with respect to timing,
frequency, or type of sexual activity can lead to sexual problems.206 Finally, power dynamics may harm a
couple’s sexual relationship. Women have been subordinated socially and economically by men for centuries
and, though they now occupy a relatively more equal position in society, this lingering inequality may make
it diﬃcult for women to feel comfortable and assertive with sexual partners.207 Even more, domestic violence
and other forms of abuse within a relationship may lead to sexual problems.
Physiological Causes
We now consider several physiological causes of sexual dysfunction in women. These causes may be rooted
in the vascular, muscular, nervous, and endocrine systems.
Beginning with vasculogenic causes, any injury to or compromise of the central arteries in the pelvic region—
the iliohypogastric/pudendal arterial bed—can decrease blood ﬂow to the genitals.208 Pelvic fracture,
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36trauma, or arteriosclerosis (the hardening and thickening of the walls of the arteries), for example, can
decrease genital blood ﬂow, reduce vaginal and clitoral engorgement, and lead to ﬁbrosis (the development
of excess ﬁbrous connective tissue) of the vaginal wall and clitoral smooth muscle.209 This, in turn, causes
disruptions in the normal vasocongestion and relaxation response to sexual stimulation and can result in
symptoms of vaginal dryness and dyspareunia.210 In a study of sexual function in women with metabolic
syndrome—a syndrome that is characterized by type II diabetes, central obesity, high blood pressure, de-
creased HDL cholesterol, and elevated triglycerides—women with the syndrome had increased rates of sexual
dysfunction as compared to controls.211 Speciﬁcally, they reported lower levels of arousal, orgasm, and lu-
brication than controls.212 Though correlation does not indicate causation, it is thought that the metabolic
syndrome may compromise genital vasocongestion and subsequently impair sexual response.213
Damage to pelvic ﬂoor muscles, which contract during sexual activity, can also reduce sexual reactivity in
women. Pelvic surgery, such as removal of the bladder (cystectomy), uterus (hysterectomy), ovaries (bilateral
oophorectomy), or colorectal re-sectioning, may disrupt pelvic nerves and change the anatomical relation-
ships of pelvic structures.214 For example, surgery for uterine prolapse or urinary incontinence may result
in damage to the anterior vaginal wall and clitoral region, which can cause arousal and orgasmic diﬃculties
as well as sexual pain disorder.215 Additionally, surgery to repair the vagina, known as colporrhaphy or
colpoperineoplasty, can narrow the vaginal opening, which can lead to pain during penetration.216
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37Neurogenic problems can also cause sexual dysfunction. Injuries to the spinal cord or diseases of the central or
peripheral nervous systems may compromise or prevent signal transduction from the brain to various muscles
in response to sexual stimuli.217 Spinal cord injuries, for example, have been shown to limit responsiveness
to sexual stimulation, and multiple sclerosis has been shown to decrease both vaginal lubrication and sexual
responsiveness in general.218
For some women, hormonal or endocrine problems are at the root of their sexual diﬃculties. Various hor-
mones are thought to be involved in female sexual response, including estrogen and testosterone. Researchers
posit that estrogen enhances blood ﬂow to the vagina and clitoris and maintains female sexual response by
preventing arteriosclerosis of the pelvic arteries and arterioles.219 Testosterone and its role in female sexual
dysfunction will be addressed in the next section of this paper, but, brieﬂy, testosterone is thought to be
involved in maintaining libido. Any condition, medication, or procedure that alters hormone levels in women,
such as hypothalamic/pituitary axis dysfunction, oral contraceptives, or surgical castration, can aﬀect sex-
ual response.220 Endocrine disease, diabetes in particular, has also been linked to sexual dysfunction. In a
study of women with type 1 diabetes, for example, Salonia et al. found that type 1 diabetics had decreased
sexual function and increased sexual distress compared to controls during the luteal phase of the menstrual
cycle.221 Speciﬁcally, subjects reported lower levels of arousal, lubrication, and orgasm and more pain dur-
ing this period than did controls.222 Though the mechanism by which diabetes aﬀects sexual functioning
remains unknown, the authors suggest it may be rooted in poor glycemic control.223
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38We have thus far reviewed normal sexual functioning and sexual dysfunction in women. Speciﬁcally, we
have discussed models of normal sexual response, classiﬁcations of sexual problems, the prevalence and pre-
sentation of these problems in women, and possible causes. We now consider one potential cause of sexual
dysfunction in women: testosterone.
Testosterone
Though the speciﬁc determinants of sexual desire in women remain poorly understood, researchers have
long theorized that androgens, speciﬁcally testosterone, play a role in female sexual response. To support
a relationship between sexual desire and androgens, researchers have looked to early anecdotal observations
that sexual desire correlates with endogenous androgen levels, that decreased sexual desire is observed in
women who have undergone oophorectomy and adrenalectomy, and that sexual desire increases following
administration of exogenous androgens.224 These early ﬁndings have led some researchers to posit that low
levels of androgens, testosterone in particular, may lead to sexual dysfunction in women.
This next section will explore such a proposition. It will begin with a discussion of basic biological infor-
mation about androgens and testosterone in women. It will then consider the few studies that look at the
relationship between testosterone levels and sexual desire in normal women. This will be followed by a
detailed exploration of the instances in which testosterone levels might be depressed in women. Speciﬁcally,
we will discuss androgen insuﬃciency, the relationships among testosterone, aging, and menopause, and the
relationship between testosterone and oophorectomy to identify when and what women might be suﬀering
224Alan Riley & Elizabeth Riley, Controlled Studies on Women Presenting with Sexual Drive Disorder: I: Endocrine Status,
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39from decreased testosterone levels and, perhaps, sexual dysfunction. Finally, this section will close with a
discussion of the association between testosterone levels and libido in surgically menopausal women (women
who have undergone oophorectomy).
As will become clear, the data on the connection between testosterone levels and sexual desire in women are
far from convincing. First, though there are studies that ﬁnd a relationship between testosterone levels and
libido in normal women, these studies have a number of methodological ﬂaws. The most recent and most
methodologically sound study fails to ﬁnd a relationship between levels of testosterone and sexual desire in
women. Nonetheless, even if we assume that low levels of testosterone are associated with decreased sexual
drive in women, there are limited instances in which women appear to suﬀer from depressed testosterone
levels. First, there is anecdotal evidence that women with hypothalamic-pituitary and adrenal conditions,
among others, may suﬀer from an androgen insuﬃciency syndrome. Second, research has shown a con-
siderably stronger connection between oophorectomy and decreased testosterone levels in women. However,
though researchers have long stated that testosterone levels decrease in women as they age and/or go through
menopause, the data do not support this proposition. In sum, the data suggest that the connection between
testosterone and sexual dysfunction exists only in women who have undergone oophorectomy.
Background Information
We begin with general information about androgens and testosterone. The term “androgens” refers to
19-carbon steroid hormones. Though they are traditionally associated with maleness and the induction of
secondary sex characteristics in men, they constitute the most plentiful sex steroids circulating in both men
40and women.225 They are thought to play an important role in maintaining reproductive function and hor-
mone homeostasis in women.226
In women, androgens are made by the ovaries, the adrenal glands (endocrine glands that sit atop the kidneys),
and peripheral tissues such as adipose tissue, muscle, and skin.227 The pituitary gland regulates, in part,
the production of androgens, because two of its secreted hormones, lutenizing hormone (LH) and adreno-
corticotropic hormone (ACTH), stimulate the production of androgens by both the ovaries and the adrenal
glands.228 In descending order of serum concentrations, the ﬁve major androgens found in women are: dehy-
droepiandrosterone sulfate (DHEAS), dehydroepiandrosterone (DHEA), androstenedione (A), testosterone
(T), and dihydrotestosterone (DHT).229 Testosterone and DHT are the most potent: if testosterone is given
a reference potency of 100, the relative potencies of the other androgens are: 300 for DHT, 10 for A, and 5
for DHEAS and DHEA.230 Androgens act on numerous tissues and receptors in the central nervous system
and peripheral sites in the body. These include the hypothalamus and limbic system as well as bone, breast,
pilosebaceous unit (the sebaceous glands in the skin), skeletal muscle, adipose, and genital tissues.231
The relationships among the various androgens are complex. Brieﬂy, in the ovaries, cholesterol is metabo-
lized to pregnenolone, the primary precursor for sex steroid synthesis.232 Testosterone, which is synthesized
from pregnenolone, can be converted to DHT in target tissues.233 DHEA and A are produced by both the
ovaries and the adrenal glands, whereas DHEAS is produced almost entirely by the adrenals.234 DHEAS,
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41DHEA, and A all serve as precursors for testosterone, and DHEAS is converted into DHEA by steroid sul-
phatase.235 Finally, testosterone, A, and DHEA are precursors for the biosynthesis of estrogens, including
estrone, estradiol, and estriol.236
Before menopause, approximately 25% of testosterone is produced by the ovaries, 25% by the adrenal glands,
and 50% from the conversion of androgen precursors—DHEAS, DHEA, and A—that are produced by the
ovaries and adrenals.237 After menopause, it is thought that the percentage production of testosterone
changes: 50% is produced by the ovaries (assuming they remain present), 10% by the adrenal glands, and
40% from precursor conversion.238 Like other hormones, testosterone moves through the body in free form or
bound to carrier proteins such as sex hormone binding globulin (SHBG) and albumin.239 SHBG has a high
aﬃnity for and binds tightly to testosterone, thus preventing it from being biologically active.240 Albumin,
however, has a much lower aﬃnity for testosterone, and as a result, testosterone can easily dissociate from
the protein and enter cells.241 Bioavailable testosterone refers to testosterone that is free, or unbound to a
carrier protein, as well as that which is bound to albumin.242
Testosterone’s mechanism of activity is both direct and indirect. The hormone aﬀects the brain directly
via androgen receptors and indirectly through the aromatization, or conversion, of testosterone to estra-
diol.243 It is also thought that testosterone directly aﬀects women’s genitalia: testosterone receptors have
been located on the vulvar epithelium, the vaginal mucosa, submucosa, stroma, and smooth muscle, and
the vascular endothelium, with the greatest degree of expression in the vaginal submucosa.244 How these
receptors function remains unknown, but they are thought to be involved in the relaxation of vaginal smooth
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42muscles.245
Researchers typically use the circulating level of testosterone in the blood as the main indicator of tissue
exposure to the hormone. There are, however, numerous concerns about this mechanism of measurement.
First, active androgens often exert their eﬀects in the same cells that synthesized them.246 Blood concentra-
tions do not capture this intracellular androgen production and metabolism and, as a result, do not measure
androgen tissue exposure or action with total accuracy.247 Second, there are diﬀerent ways of measuring
serum concentrations of free testosterone, and the reliability and comparability of each measure varies. For
example, Miller et al. conducted a study comparing three diﬀerent common methods of measuring serum
free testosterone: equilibrium dialysis, direct radioimmunoassay (RIA), and the law of mass action.248 The
study found that calculated free values of testosterone using equilibrium dialysis and the law of mass action
correlated well, whereas RIA measurements did not and also exhibited unacceptably high systematic bias
and random variability.249 A third concern is that current assays show poor reliability at the lower end of
the spectrum of circulating testosterone in females.250
Additionally, variations in testosterone levels among and even within women can make measuring these levels
problematic. Speciﬁcally, what constitutes a “normal” level of an androgen may vary from woman to woman.
In their study of circulating androgen levels in women, for example, Lasley et al. found that baseline levels
of DHEAS, which correlate with testosterone levels, appear to vary across ethnic groups, with concentra-
tions being highest among Chinese and Japanese and lowest among African Americans and Hispanics.251
Furthermore, women’s testosterone levels exhibit diurnal and monthly ﬂuctuations. Each day, testosterone
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43levels peak early in the morning, and each month, testosterone levels ﬂuctuate in accordance with the normal
menstrual cycle.252 In the early follicular phase, when menstruation occurs, testosterone concentrations are
lowest.253 They peak midcycle, around the same time that estrogen levels peak and ovulation occurs.254
During the luteal phase, when the endometrial lining proliferates in preparation for pregnancy, testosterone
levels are higher than they are during the early follicular phase.255 These normal variations in concentra-
tions among and within women can make it diﬃcult to determine what constitutes a “normal” testosterone
concentration (a measurement in the morning? At midcycle?) and to compare women’s testosterone levels.
(Can measurements taken during the follicular phase be compared to measurements taken during the luteal
phase?) A recent consensus statement on female androgen insuﬃciency proposed standards for measuring
androgen levels in women, and it recommended obtaining measures of free and total testosterone levels in
the morning hours and in the middle third of the menstrual cycle (early luteal phase) when levels are high
but not peaking.256
Testosterone and Sexual Function in Normal Women
We now consider the data examining the relationship between testosterone levels and sexual dysfunction in
healthy women. As we will discuss, the data are mixed. There are several studies that ﬁnd low levels of
testosterone in women with sexual dysfunction, but these studies uniformly suﬀer from methodological ﬂaws,
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44including small subject pools and no control groups. The most recent, and most methodologically sound,
study found no relationship between testosterone levels and sexual function in healthy women.
We begin with the studies that ﬁnd a relationship. Riley & Riley compared hormone proﬁles of 15 women
with sexual drive disorder (or absence of sexual drive) with those of 15 women without any sexual functioning
problems.257 The results indicated that, though patients and controls had hormone levels within normal
ranges and though there was no diﬀerence in total testosterone levels between the groups, levels of free
testosterone were signiﬁcantly lower in the patient group than in the control group.258 It is important to
note, however, that the sample size was very small and that each woman provided only one blood sample.259
Furthermore, though researchers tried to obtain each sample as close to mid-menstrual cycle as possible, the
timing was neither precisely at mid-cycle nor uniform among the subjects.260
Guay examined total and free testosterone levels in 12 premenopausal women complaining of decreased
libido.261 Of the 12 women, 8 had low or immeasurable levels of total and free testosterone.262 Again,
this study contained few subjects and, because it did not include a control group, Guay was not able to
compare the results to testosterone levels in healthy controls. In another study, Guay & Jacobson measured
total testosterone, free testosterone, and DHEAS in 105 premenopausal and postmenopausal women with
decreased sexual desire.263 Of the 105 women, 74 (70%)—36 of which were premenopausal and 38 of
which were postmenopausal—had decreased total testosterone, free testosterone, and DHEAS.264 As in prior
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45research by Guay, this study included no controls.265 Finally, Guay et al. examined ovarian and adrenal
androgens in 32 healthy premenopausal women, 18 with one or more complaints of sexual dysfunction and
14 without any such complaints. 266 Women with complaints of sexual dysfunction had signiﬁcantly lower
levels of total and free testosterone when compared to women without sexual dysfunction.267 Though this
study did include controls, it, like Guay’s other research, included very few subjects.
In contrast, some studies have failed to ﬁnd a relationship between testosterone levels and sexual function.
Nyunt et al., for example, measured androgen levels in 29 female volunteers with reduced libido and 12
controls.268 The authors found no signiﬁcant diﬀerence between subjects and controls with respect to serum
testosterone or free testosterone levels.269 However, signiﬁcantly more women with loss of libido reported a
history of depression or a low income than did women without sexual dysfunction.270 The authors concluded
that psychosocial factors and health status, rather than androgen status, appeared to be more important in
diﬀerentiating between females with and without loss of libido.271
Davis et al. conducted the largest and most methodologically sound inquiry into the relationship between
self-reported sexual function and circulating androgen levels.272 The study assessed androgen concentrations
and sexual desire, arousal, orgasm, pleasure, responsiveness, and self-image in 1021 women between the ages
of 18 and 75.273 The study found that there was no relationship between levels of total or free testosterone
265Id.
266A. Guay et al., Serum Androgen Levels in Healthy Premenopausal Women With and Without Sexual Dysfunction: Part
B: Reduced Serum Androgen Levels in Healthy Premenopausal Women With Complaints of Sexual Dysfunction, 16 Int’l J.
Impotence Res. 121, 121 (2004).
267Id.
268A. Nyunt et al., Androgen Status in Healthy Premenopausal Women with Loss of Libido, 31 J. Sex & Marital Therapy
73, 75 (2005).
269Id. at 77.
270Id. at 76.
271Id.
272Davis et al., supra note 246, at 91.
273Id. at 92.
46and any of the domains of sexual functioning, including sexual desire, arousal, and responsiveness.274
Thus, there appears to be data for and against the proposition that low levels of testosterone may be associ-
ated with sexual dysfunction in women. However, all the studies that ﬁnd a relationship have either very few
subjects or no controls, so it is unclear whether the association is statistically signiﬁcant. Furthermore, with
the exception of Riley & Riley’s study, Guay conducted all the studies. In light of the lack of methodological
breadth and rigor, it is diﬃcult to take this research as much more than anecdotal evidence that women
with low libido might have low testosterone levels. On the other hand, there are fewer studies that ﬁnd no
relationship between testosterone and sexual dysfunction. Though Davis et al. is an impressive and more
credible study—with 1021 women and published in JAMA—it has not yet been replicated. In conclusion,
the relationship between testosterone and sexual dysfunction in women remains unclear and needs to be
researched further.
Changes in Testosterone Levels
In this section, we assume that there is a relationship between low levels of testosterone in women and
libido, and we seek to identify when women might be suﬀering from depressed testosterone concentrations.
This, in turn, can help determine for which populations of women testosterone might be the cause of sexual
dysfunction. We examine three cases: female androgen insuﬃciency, the eﬀects of aging and menopause on
testosterone, and oophorectomy and testosterone.
Female Androgen Insuﬃciency
274Id. at 93.
47In recent years, researchers have posited the existence of a female androgen insuﬃciency syndrome that
is distinguished by a pattern of clinical signs and symptoms accompanied by decreased levels of bioavail-
able testosterone and normal estrogen levels.275 Though clinical observations and intervention trials have
provided some evidence of an androgen insuﬃciency syndrome in women, there have yet to be large-scale
epidemiological studies that conﬁrm its existence.
Despite the shaky evidence, a recent consensus statement proposed a deﬁnition of androgen insuﬃciency
in women.276 First, the following clinical symptoms must be present: a diminished sense of wellbeing
or dysphoric mood, persistent and unexplained fatigue, and sexual function changes, including decreased
libido, sexual receptivity, and pleasure.277 Other symptoms include vasomotor instability, decreased vaginal
lubrication, bone loss, decreased muscle strength, and changes in cognition or memory.278 Second, estrogen
levels must be normal, as estrogen can also be involved in mood, psychological wellbeing, and sexual function
and must therefore be ruled out as a cause.279 Third, free testosterone levels must be at or below the lowest
quartile of the normal range for women in their reproductive years.280
The potential causes of female androgen insuﬃciency are numerous. They include hypothalamic-pituitary,
ovarian, and adrenal conditions as well as drug-use and various diseases.281 Speciﬁcally, pituitary insuﬃ-
ciency from adenomas (benign tumors) or hypophysitis (inﬂammation) or other forms of destruction can
block the production of LH and ACTH, which can then result in insuﬃcient androgen production by the
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48ovaries and adrenals.282 Ovarian destruction by chemotherapy and radiation therapy can lead to reduced an-
drogen production, as can adrenal insuﬃciency and adrenalectomy.283 Certain drugs, such as corticosteroids,
antiandrogenic agents, oral contraceptives, and oral estrogen replacement therapies, can block ovarian and
adrenal function and thereby decrease androgen output.284 Finally, other diseases have been implicated in
reducing androgen production, including anorexia nervosa and immunologic disorders such as rheumatoid
arthritis, systemic lupus erythematosus, and HIV-AIDS.285
Few studies have actually examined androgen levels in patients with conditions associated with androgen
insuﬃciency. A 1959 study by Waxenberg et al. found sexual problems the researchers deemed characteristic
of androgen insuﬃciency in a group of 29 women who had undergone adrenalectomy and bilateral oophorec-
tomy for metastatic breast cancer.286 After their operations, the women reported decreases in sexual desire,
sexual activity, and responsiveness, which the authors stated were consequences of decreased androgen lev-
els.287 However, the study never actually measured androgen levels to conﬁrm androgen insuﬃciency, and
its subject were all fatally ill with cancer. These ﬂaws limit the study’s generalizability. Kaplan & Owett
replicated Waxenberg et al.’s study, though they did measure subjects’ androgen levels.288 The authors ex-
amined 11 women who had undergone chemotherapy and/or bilateral oophorectomy for carcinomas or other
medical conditions, and they found that 10 of the 11 patients exhibited low levels of circulating testosterone
levels in comparison to normal controls.289 In their study, ovarian destruction was associated with androgen
deﬁciency.
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49An additional study by Miller et al. inquired into the androgen concentrations of 55 women with acquired hy-
popituitarism (the majority of which were from pituitary adenomas) characterized by hypogonadism and/or
hypoadrenalism.290 The study found that, regardless of age and treatment with estrogen, all subjects had
markedly reduced levels of serum testosterone, free testosterone, androstenedione, and DHEAS when com-
pared to controls.291 Furthermore, levels of serum testosterone, free testosterone, and androstenedione were
lower in women with both hypogonadism and hypoadrenalism than in women with hypogonadism or hypoa-
drenalism alone.292 Though there are limited data on the topic, it appears that certain conditions, such as
hypopituitarism and hypoadrenalism, may result in androgen insuﬃciency and in decreased concentrations
of testosterone in women.
Testosterone, Aging, and Menopause
The exact progression of testosterone levels over the course of a woman’s lifetime remains unclear. The
majority of review articles state that testosterone levels decrease over time293 and that this decline is the
result of natural aging rather than menopause.294 However, the data are far from uniform on this subject,
and the precise nature of the relationships among testosterone, menopause, and aging remains unresolved.
Speciﬁcally, there is research that indicates that testosterone levels fall over time, that testosterone levels
fall before or at menopause but begin to increase shortly after the climacteric, that levels remain unchanged
over the lifespan, and that levels increase slightly late in women’s lives. We consider all this data in turn.
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50Many researchers posit that testosterone levels decrease over time as a function of age. For example, Zumoﬀ
et al. examined testosterone levels in a cross-sectional study of 33 healthy, regularly cycling, nonobese women
between the ages of 21 and 51.295 The data indicated that mean plasma concentration of testosterone declined
steeply with age, such that women in their 40’s had half the testosterone concentration as women in their
20’s.296 Lasley et al. conducted a considerably larger prospective study in which they measured androgen
levels over 2 years in 3,000 women aged 42 to 54.297 This study found a 26% decline in mean testosterone
levels between 42 and 50 years of age, with the majority of the drop occurring in the early 40’s.298 However,
testosterone levels began to increase slightly in late perimenopausal women between the ages of 50 and 52.299
Other longitudinal research has suggested that, though levels of testosterone may decrease at middle age,
this decline is temporary. An early study by Chakravarti et al. inquired into endocrine changes in 60
postmenopausal women between the ages of 49 and 91.300 The results indicated that, ﬁve years after
menopause, testosterone levels fell.301 However, in the next three decades, testosterone levels increased.302
Another study by Laughlin et al. examined the hysterectomy and oophorectomy status and androgen levels
of women between the ages of 50 and 89.303 The results indicated that, in the 438 women who had not
undergone hysterectomy or oophorectomy, testosterone levels decreased around the time of menopause.304
However, for women who were 20 years past menopause or who were 70 years of age or older, levels of
295Barnett Zumoﬀ et al., Twenty-Four-Hour Mean Plasma Testosterone Concentration Declines with Age in Normal Pre-
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51testosterone were comparable to premenopausal levels, indicating that decreases in testosterone levels around
the time of menopause may be transient.305 Overlie et al. also found an increase in ovarian testosterone
production after menopause and a movement towards premenopausal levels.306 Speciﬁcally, testosterone
levels dropped 20% during perimenopause but increased the following two years.307
The majority of data indicates that testosterone levels are unrelated to aging and menopause and do not
change over time. In a cross-sectional study of 155 women between the ages of 34 to 83, all of whom had
been postmenopausal for at least one year (the younger women had experienced premature ovarian failure),
Meldrum et al. found that testosterone levels did not change with age.308 Another cross-sectional study by
Labrie et al. examined 60 women between the ages of 20 and 80 and, again, found no signiﬁcant or consistent
change in serum testosterone levels over time.309
Cauley et al. examined the eﬀects of certain environmental factors, including obesity, physical activity,
muscle strength, and alcohol consumption as well as age and menopausal status, on androgen levels in
a cross-sectional sample of 176 healthy postmenopausal women.310 Univariate analyses failed to show a
relationship between testosterone levels and age and between testosterone levels and time since menopause.311
Multiple regression analysis also failed to ﬁnd such relationships, though there was a borderline signiﬁcant
positive correlation between obesity and testosterone levels.312 Bancroft & Cawood also conducted a cross-
sectional study of 141 women aged 40 to 60 that examined the relative contributions of environmental factors,
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52age, and menopausal status on androgen levels.313 Though univariate analyses suggested that testosterone
decreased with age, this relationship disappeared when other variables were introduced in a multivariate
regression.314 Speciﬁcally, testosterone levels were positively correlated with levels of androstenedione and
lutenizing hormone as well as body-mass index.315 Finally, Burger et al. studied average androgen levels in
a population of 172 women over a period of seven years.316 Mean testosterone levels did not vary across the
time period, indicating that testosterone levels were unrelated to both menopausal status and age.317
Finally, some research suggests that testosterone levels may actually increase over time. Judd et al., an
early study, found testosterone concentrations in the ovarian veins of 10 postmenopausal women to be twice
the magnitude of those in premenopausal women.318 The authors interpreted this data as suggesting that
ovarian testosterone secretions may be larger in postmenopausal women than in premenopausal women.319 A
more recent study by Jiroutek et al. examined changes in circulating hormones in 32 postmenopausal women
for approximately 10 years.320 The study found a signiﬁcant increase in the concentration of testosterone
over time, the majority of which occurred during the later years of the follow-up.321
As shown by the numerous contradictory studies, whether and how testosterone levels change over time is far
from clear. To further complicate the matter, most of the aforementioned studies suﬀer from methodological
313John Bancroft & Elizabeth H. Cawood, Androgens and the Menopause: A Study of 40-60-Year-Old Women, 45 Clinical
Endocrinology 577, 578 (1996).
314Id. at 584.
315Id.
316Henry G. Burger et al., A Prospective Longitudinal Study of Serum Testosterone, Dehydroepiandrosterone Sulfate, and
Sex Hormone-Binding Globulin Levels Through the Menopause Transition, 85(8) J. Clinical Endocrinology & Metabolism
2832, 2833 (2000).
317Id. at 2838.
318Howard L. Judd et al., Endocrine Function of the Postmenopausal Ovary: Concentration of Androgens and Estrogens in
Ovarian and Peripheral Vein Blood, 39(6) J. Clinical Endocrinology & Metabolism 1020, 1022 (1974).
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320Michael R. Jiroutek et al., Changes in Reproductive Hormones and Sex Hormone-Binding Globulin in a Group of Post-
menopausal Women Measured Over 10 Years, 5(2) J. N. Am. Menopause Soc’y 90, 90 (1998).
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53ﬂaws.322 The majority are cross-sectional and, rather than observing testosterone levels in a sample of
women over time, they compare levels of testosterone in women of diﬀerent ages. For example, Meldrum et
al. compared the testosterone levels of women between the ages of 34 and 83,323 and Labrie et al. compared
the testosterone levels of women between the ages of 20 and 80.324 This is potentially problematic because
individual physiology varies: what constitutes a “normal” level of testosterone in one woman may be a “low”
level of testosterone in another. Additionally, many studies are based on small convenience or clinic samples
with inherent biases, which makes it diﬃcult to generalize the ﬁndings.325 For example, the study by Zumoﬀ
et al. is the most widely cited study for the proposition that testosterone levels decrease as a result of aging
in women, and yet this ﬁnding was based on testosterone samples from only 33 women.326 Judd et al.,
another frequently cited study, included only 10 women.327 As a ﬁnal point, there are no comprehensive
studies of a single cohort of women throughout their lives. Burger et al. examined the same women over a
period of seven years,328 but seven years does not constitute a lifetime.
Methodological considerations notwithstanding, it is diﬃcult to synthesize the data in a coherent, meaningful
way. However, taken together, the data suggest that it is far from patent that testosterone levels decrease
with age and that, on the contrary, the bulk of studies point towards no change over time. The studies
that are the most methodologically sound—Lasley et al.329 and Laughlin et al.330 (both of which included
relatively more subjects, 3,000 and 438 respectively, compared to other studies), Cauley et al.331 and
Bancroft & Cawood332 (which considered mediating environmental factors and conducted multivariate as
322See Lorraine Dennerstein et al., Hormones, Mood, Sexuality, and the Menopause Transition, 77(4) Fertility & Sterility
(Supp. 4) S42, S42 (2002) for commentary on methodological ﬂaws in studies examining hormone levels in women across the
lifespan.
323Meldrum et al., supra note 308, at 627.
324Labrie et al., supra note 309, at 2397
325Dennerstein et al., supra note 322, at S42.
326Zumoﬀ et al., supra note 295, at 1429.
327Judd et al., supra note 318, at 1022.
328Burger et al., supra note 316, at 2833.
329Lasley et al., supra note 251, at 3760.
330Laughlin et al., supra note 303, at 645.
331Cauley et al., supra note 310, at 1122, 1127.
332Bancroft & Cawood, supra note 313, at 584.
54well as univariate analyses), and Burger et al.333 (which was a longitudinal study rather than a cross-
sectional study)—tend to suggest that testosterone levels remain relatively stable over time and that any
age related decreases are short-lived.
Testosterone and Oophorectomy
In contrast to the mixed data on testosterone, aging, and menopause, the data on the eﬀect of bilateral
oophorectomy,334 or the surgical removal of both ovaries, on testosterone levels in women are relatively
clear. Speciﬁcally, the data indicate that the removal of both ovaries results in a decrease in testosterone
levels. This section will begin with background data on oophorectomy and hysterectomy and will then
describe several studies that illustrate the relationship between oophorectomy and testosterone levels.
When both ovaries are removed, a hysterectomy, or the removal of the uterus, is almost always performed
at the same time.335 Hysterectomy with and without oophorectomy is one of the most common procedures
performed on women in the United States. Wilcox et al. reported that, between 1988-1990, 1.7 million women
(or 600,000 a year) had a hysterectomy.336 The highest rate—100.5 hysterectomies per 10,000 women—was
for women between the ages of 30 and 54.337 Of the women undergoing hysterectomies, 37% of women
under the age of 45 and 68% over the age of 45 underwent concomitant bilateral oophorectomy.338 In total,
approximately 50% of women having a hysterectomy also have their ovaries removed.339 A more recent study
by Farquhar & Steiner found that the rates of hysterectomy did not change signiﬁcantly over the period of
333Burger et al., supra note 316, at 2833.
334Note that the terms bilateral oophorectomy and oophorectomy are used interchangeably to refer to the surgical removal of
both ovaries.
335The Boston Women’s Health Book Collective, Our Bodies, Ourselves For the New Century 666-667 (3rd. ed.
1998).
336L.S. Wilcox et al., Hysterectomy in the United States, 1988-1990, 83(4) Obstetrics & Gynecology 549, 549 (1994).
337Id.
338Id.
339Id.
551990-1997 and appear level at 500,000 to 600,000 women per year.340
Common reasons for the removal of the ovaries include endometriosis, pelvic inﬂammatory disease, ectopic
pregnancy, and malignant tumors on the ovary.341 Hysterectomies are performed in cases of pelvic inﬂamma-
tory disease, severe and uncontrollable bleeding, and invasive cancer of the uterus, cervix, vagina, fallopian
tubes and/or ovaries.342 Hysterectomies are sometimes performed for endometriosis, ﬁbroid tumors, pelvic
relaxation (uterine prolapse), and precancerous changes of the endometrium.343
The eﬀect of oophorectomy on circulating androgen levels has long been a subject of inquiry. An early study
by Judd et al. measured testosterone and androstenedione levels in 5 premenopausal and 16 postmenopausal
women before and 6 to 8 weeks after bilateral oophorectomy as treatment for endometrial cancer.344 After
surgery, testosterone levels fell 57% in premenopausal women and 54% in postmenopausal women.345 Hughes
et al. also found that women who had had their ovaries removed experienced a considerable decline in serum
testosterone levels.346 Hughes et al. examined reproductive hormones in 11 postmenopausal women who had
undergone pelvic surgery that included bilateral oophorectomy and found that testosterone levels dropped
by half in these patients.347 Though the drop in testosterone levels after oophorectomy was unmistakable in
these two studies, the generalizability of these results is questionable. Speciﬁcally, both used cancer patients
340Cynthia M. Farquhar & Claudia A. Steiner, Hysterectomy Rates in the United States 1990-1997, 99(2) Obstetrics &
Gynecology 229, 230-231 (2002).
341The Boston Women’s Health Book Collective, supra note 335, at 667.
342Id. at 663.
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344Howard L. Judd, William E. Lucas, & Samuel S. C. Yen, Eﬀect of Oophorectomy on Circulating Testosterone and An-
drostenedione Levels in Patients With Endometrial Cancer, 118(6) Am. J. Obstetrics & Gynecology 793, 793 (1974).
345Id. at 795-796.
346Claude L. Hughes et al., Reproductive Hormone Levels in Gynecologic Oncology Patients Undergoing Surgical Castration
After Spontaneous Menopause, 40(1) Gynecologic Oncology 42, 42 (1991).
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56as subjects, and hormone production and hormone levels may be abnormal in individuals with cancer.348
Laughlin et al., a more recent population-based longitudinal study, examined endogenous sex hormone levels
for a period of 4 years in 684 older women, some of whom had undergone hysterectomy and/or oophorectomy
many years earlier and some of whom had not (“intact” women).349 The results indicated that women who
had undergone hysterectomy with bilateral oophorectomy had a substantial and sustained reduction in total
and bioavailable testosterone levels: these levels were reduced by more than 40% in comparison to levels
in intact women.350 Women who had undergone hysterectomy but retained their ovaries had total and
bioavailable testosterone levels that were lower than levels in intact women but higher than levels in women
who had had a hysterectomy and oophorectomy.351 Presumably, given that these women had retained their
ovaries, their testosterone levels should have been comparable to those of intact women.352 The authors
suggest that damage to the ovarian artery during surgery might have led to functional impairment or failure
of one or both ovaries and subsequent reduced production of testosterone.353
Testosterone and Sexual Function in Oophorectomized Women
Thus far, we have seen that the evidence for a relationship between testosterone and sexual function in
normal women is slim. We have also seen that there appears to be evidence for depressed testosterone
levels only in women who have undergone oophorectomy, as opposed to women with androgen deﬁciency
348Judd et al., supra note 344, at 795.
349Laughlin et al., supra note 303, at 645.
350Id. at 648-649.
351Id. at 649.
352Id.
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57or older/menopausal women. In this section, we consider whether depressed testosterone levels are related
to a decline in sexual functioning in oophorectomized women. We ﬁrst consider studies that look at sex-
ual function in women after they have undergone oophorectomy, and we then consider studies that treat
oophorectomized women with sexual dysfunction with testosterone.
The data indicate that women who have undergone oophorectomy can experience concurrent declines in
testosterone levels and sexual function. Early research by Waxenberg et al. found adrenalectomy and bi-
lateral oophorectomy to be associated with impairment in sexual function.354 Speciﬁcally, the majority of
subjects who reported preoperative sexual desire, sexual activity, and sexual responsiveness experienced a
loss of desire, a decrease in sexual activity, and a loss of responsiveness after surgery.355 As mentioned earlier,
problems with this study include the small sample (29 women), the lack of controls, the failure to measure
testosterone, and the presence of cancer. In a similar study, Kaplan & Owett examined 11 women who
had undergone chemotherapy and/or bilateral oophorectomy and who had normal sexual functioning prior
to cancer treatment.356 After treatment, all the women exhibited low levels of circulating testosterone in
comparison to normal controls as well as markedly decreased or absent sexual desire and orgasm.357 Again,
the study had methodological problems—the small sample size, the presence of cancer, and the fact that
testosterone levels and sexual function were not assessed before treatment—but it nonetheless pointed to an
association between decreased testosterone and depressed sexual function in women without their ovaries.
Another study compared sexual function in women who had undergone hysterectomy and oophorectomy to
sexual function in women who had undergone hysterectomy with ovary preservation.358 The results indi-
cated that women who had their ovaries removed reported less pleasure from intercourse and impaired libido
354Waxenberg et al., supra note 286, at 194-195.
355Id.
356Kaplan & Owett, supra note 288, at 3.
357Id. at 10.
358J. Nathorst-Boos, B. von Schoultz, & K. Carlstr¨ om, Elective Ovarian Removal and Estrogen Replacement Therapy—Eﬀects
on Sexual Life, Psychological Well-Being, and Androgen Status, 14 J. Psychosomatic Obstetrics & Gynaecology 283, 286
(1993).
58and lubrication in comparison to women who retained their ovaries, suggesting that ovary removal and the
concurrent drop in testosterone levels are associated with sexual impairment.359 Shifren et al. examined
75 women who had undergone hysterectomy and bilateral oophorectomy and who felt that their sex lives
were active and satisfying before undergoing surgery.360 After their operations, these women had markedly
impaired sexual function in comparison to normal women of similar age.361 Speciﬁcally, they reported lower
levels of desire, arousal, frequency of sexual activity, and pleasure/orgasm.362
These studies indicate that oophorectomy, which appears to cause a drop in testosterone levels, can be
associated with decreases in sexual functioning. This also suggests that in women without their ovaries, de-
pressed testosterone levels may result in sexual problems. In response to this data, researchers have treated
oophorectomized women with sexual dysfunction with testosterone and have seen improvements in sexual
functioning. Several of these studies are discussed below.
Sherwin et al. put a group of women who had undergone hysterectomy and bilateral oophorectomy on
estrogen and/or androgen replacement therapy.363 The results indicated that sexual desire, sexual fantasy,
and sexual arousal were signiﬁcantly higher in women on androgen and estrogen-androgen replacement
therapy than in women on estrogen or placebo.364 However, androgen treatment had no eﬀect on physiologic
response (frequency of intercourse or orgasm) or interpersonal aspects of sexual behavior; its primary impact
appeared to be on sexual motivation—fantasies, desire, and arousal—rather than on sexual activity.365
In another study, Sherwin & Gelfand examined whether androgenic eﬀects on sexual behavior would be
359Id. at 288.
360Jan L. Shifren et al., Transdermal Testosterone Treatment in Women with Impaired Sexual Function After Oophorectomy,
343 New Eng. J. Med. 682, 683 (2000).
361Id. at 686.
362Id. at 687.
363Barbara B. Sherwin, Morrie M. Gelfand, & William Brender, Androgen Enhances Sexual Motivation in Females: A
Prospective, Crossover Study of Sex Steroid Administration in the Surgical Menopause, 47(4) Psychosomatic Med. 339,
340 (1985).
364Id. at 345.
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59enduring.366 In this study, the subjects had undergone hysterectomy and bilateral oophorectomy for benign
disease approximately 4 years prior to the study and had been on an estrogen-androgen preparation (22
subjects), estrogen alone (11 subjects), or no treatment (11 subjects) for approximately 2 years.367 The
results indicated that women who received estrogen-androgen therapy had signiﬁcantly more sexual desire,
arousal, and sexual fantasies compared to women on estrogen alone or on no treatment.368 Furthermore,
changes in these behaviors covaried with levels of testosterone: sexual desire, arousal, and fantasy levels as
well as testosterone levels were greatest the week following injection and decreased over the course of the
following two weeks.369 Additionally, for the ﬁrst two weeks after injection, rates of intercourse and orgasm
were higher in the estrogen-androgen treatment group than in the estrogen and no treatment groups.370 This
suggests that the researchers’ prior ﬁnding that testosterone did not aﬀect sexual activity may have been
due to the fact that subjects had not yet recovered fully physically from having surgery.371 It is important
to note, however, that this study was not blind—both researchers and subjects knew what, if any, treatment
subjects were receiving—and there was no use of placebo.
Shifren et al. also found testosterone treatment to be associated with increased sexual wellbeing in oophorec-
tomized women.372 This study examined 75 women who had undergone hysterectomy and bilateral oophorec-
tomy and were suﬀering from sexual dysfunction.373 Over three 12-week treatment periods, subjects were
given, in random order, two placebo patches (no active drug), one active and one placebo patch (nominal
366Barbara B. Sherwin & Morrie M. Gelfand, The Role of Androgen in the Maintenance of Sexual Functioning in Oophorec-
tomized Women, 49 Psychosomatic Medicine 397, 398 (1987).
367Id. at 399.
368Id. at 401-403.
369Id.
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372Shifren et al., supra note 360, at 683.
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60dose of testosterone—150µg per day), and two active patches (300µg per day).374 Both the placebo and
testosterone treatments improved sexual functioning.375 Speciﬁcally, the authors noted a strong placebo
response, with all indexes of sexual functioning increasing (composite score, thoughts/desire, arousal, fre-
quency of sexual activity, receptivity/initiation, pleasure/orgasm, and relationship satisfaction).376 Testos-
terone treatment resulted in further increases in each index, but the only statistically signiﬁcant results were
increases in the composite sexual functioning score, frequency of sexual activity, and pleasure/orgasm that
were associated with 300µg testosterone treatment.377
These studies suggest that testosterone treatment improves sexual functioning in women who no longer have
their ovaries. It is important to note, however, that the studies by Sherwin et al. and Sherwin & Gelfand
were not blind and did not include placebo groups. This is especially signiﬁcant in light of the considerable
placebo eﬀect found by Shifren et al. Furthermore, it is not clear whether some or all aspects of sexual
functioning are improved by treatment with testosterone. Finally, the subjects in these studies knew they
were involved in research on sexual functioning, and it is possible that this knowledge might have aﬀected or
improved their sexual relationships. Subjects may, for example, have communicated more with their partners
or engaged in more sexual activity.378
We have thus far reviewed the relationship between female sexual dysfunction and testosterone. We have
seen that there is little evidence for a causal relationship between decreased testosterone levels and sexual
problems in normal women, and we have seen that few populations of women have depressed testosterone
levels. Women who have undergone oophorectomy, however, appear to exhibit low levels of testosterone,
and these depressed concentrations may result in sexual diﬃculties. At this point, we consider Intrinsa, a
testosterone treatment for female sexual dysfunction, and the controversy surrounding its development and
374Id.
375Id. at 685.
376Id.
377Id.
378Shifren et al., supra note 360, at 687.
61its rejection by the FDA.
Intrinsa
In 2004, Proctor & Gamble (“P&G”) submitted its drug, Intrinsa, for approval by the FDA.379 Intrinsa
is a testosterone transdermal system (“TTS”), or a 28 cm3 patch that contains 8.4 mg of testosterone.380
It delivers approximately 300 mcg/day of testosterone when worn on the abdomen and changed twice a
week.381 P&G proposed Intrinsa as treatment for hypoactive sexual desire disorder in women without their
ovaries (“surgically menopausal” women).382
Intrinsa was evaluated over a series of seven clinical trials, though the last two Phase 3 trials were the central
studies submitted to support the drug’s safety and eﬃcacy. Each Phase 3 study was a 24-week, randomized,
double-blind, placebo-controlled design that was followed by a 28-week open label period.383 All subjects
were between 20 and 70 years old, had undergone oophorectomy and hysterectomy at least 6 months prior
to the study, were receiving estrogen, and had been in a stable, monogamous relationship for at least 1
year prior to entering the study.384 Additionally, all subjects reported satisfying sex lives prior to surgery
and had experienced postoperative decreases in sexual desire and activity that caused them distress.385
However, unlike Phase 2 trial subjects, Phase 3 subjects were not required to have low levels of testosterone
379Proctor & Gamble Pharmaceuticals, Inc., Advisory Committee Brieﬁng Document: Intrinsa (Testosterone Transdermal
System) (Dec. 2, 2004), http://www.fda.gov/ohrms/dockets/ac/04/brieﬁng/2004-4082B1 01 A-P&G-Intrinsa.pdf.
380Id. at 15.
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382Id. at 4.
383Id. at 26.
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385Id. at 27.
62to participate in the study.386
For the ﬁrst Phase 3 trial, 283 women received 300 mcg/day TTS, and 279 received a placebo patch.387 For
the second, 266 women received 300 mcg/day TTS, and 266 received a placebo patch.388 After 24 weeks,
both placebo groups were switched to 300 mcg/day TTS, and both active groups remained on testosterone
treatment for another 28 weeks.389 Intrinsa’s eﬃcacy was measured by assessing the change in the 4-week
frequency of total satisfying sexual episodes (“SSEs”) from baseline to week 24.390 The study also assessed
changes in personal distress and sexual desire.391
Generally, the results indicated that the women receiving testosterone experienced a statistically signiﬁcant
increase in frequency of satisfying sexual episodes as well as a decrease in personal distress and an increase
in sexual desire that were statistically signiﬁcant.392 Speciﬁcally, for the ﬁrst Phase 3 trial, the placebo
group experienced a mean increase of 0.98 SSEs per 4 weeks (from 3 to 4 events), and the treatment group
experienced a 2.13 mean increase (from 3 to 5 events).393 In the second Phase 3 trial, the placebo group
reported an increase of 0.73 (from 3 to 4 events) and the treatment group an increase of 1.56 (from 3 to 4.5
events).394 The increases experienced by the treatment groups (approximately 1 satisfying sexual event per
4 weeks more than the controls) reached statistical signiﬁcance.395 Additionally, though both placebo and
treatment groups reported decreased personal distress and increased sexual desire, the changes the treatment
groups experienced were signiﬁcantly greater than those experienced by the placebo groups.396
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63With respect to side eﬀects, the researchers concluded that Intrinsa had a favorable safety proﬁle. During the
course of the trials, there was only one death: a woman in the placebo group died from a brain hemorrhage.
397 Additionally, three women in the treatment group and one woman in the placebo group were diagnosed
with breast cancer, but the researchers noted that these numbers were consistent with breast cancer rates in
middle-aged women.398 Though there were no heart attacks during the studies, one woman in the treatment
group suﬀered a transient ischemic attack and another experienced an “episode of tightness in the chest,
diarrhea, ﬂushing, increased heart rate, nausea, tingling in roof of mouth, and diaphoresis.”399 Both adverse
events resolved while the women were still on testosterone.400 Generally, the testosterone and placebo groups
exhibited similar overall adverse events, with the most common being application site reactions.401 In one
study, subjects on testosterone reported slightly more acne and hirsutism (hair growth) than did controls,
but these events were mild and did not cause subjects to discontinue treatment.402
In its instructions to the Advisory Committee on Reproductive and Urologic Drug Products, the FDA
requested that the Committee consider three points.403 First, the Committee was asked to determine
whether the increase of one satisfying sexual event per 4 weeks more in the testosterone group than in
the placebo group was clinically meaningful.404 Second, the Committee was to examine the safety data on
Intrinsa in light of the recently discovered risks of hormone replacement therapy.405 Finally, the FDA asked
the Committee to determine whether unanswered safety questions remained.406
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64Ultimately, the FDA refused to approve Intrinsa. Though the Advisory Committee noted that the increase
in satisfying sexual episodes in the treatment group was clinically meaningful, it concluded that P&G’s safety
data did not assuage its concerns about the long-term health eﬀects of testosterone treatment in women.407
The Committee was concerned that the sample sizes and duration of P&G’s prior and future safety studies
were insuﬃcient to determine increases in adverse events (above background rates) that were caused by
Intrinsa.408 The Advisory Committee stated that only a prospective, long-term randomized, controlled
study “of suﬃcient power” would provide meaningful answers about the long-term risks of Intrinsa.409
The Controversy
Intrinsa itself and the FDA’s denial of approval caused considerable controversy among sexual health scholars
and researchers. Some found fault with the development of the drug, arguing that Intrinsa was the result of
the pharmaceutical industry’s eﬀorts to create a disease for pecuniary gain. Others criticized the FDA for
basing its rejection of the drug on inappropriate grounds and for setting unattainable safety standards. The
following section discusses both controversies. It concludes by considering Intrinsa and the FDA’s decision
in light of the issues discussed in the prior two sections of this paper.
The Making of a Disease
407FDA Panel Rejects P&G’s Intrinsa for Boosting Women’s Sex Drive, 3011 Informa 21, 21 (2004).
408Food & Drug Administration, Intrinsa (Testosterone Transdermal System): Review by the Division of Reproductive
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Intrinsa-Medical-Review.pdf.
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65The pharmaceutical industry has long been accused of inventing diseases to promote drug development and
sales, and many scholars viewed the creation of Intrinsa as the industry’s latest eﬀort to fashion and promote
a disorder. After Viagra’s considerable success, it is thought that the pharmaceutical industry sought to build
a similar market for such drugs for women. Speciﬁcally, experts accused the industry of working to redeﬁne
female sexual dysfunction to create clearly described medical conditions with measurable characteristics such
that it could develop and sell drugs as treatment.410 Furthermore, once the industry had recharacterized
sexual problems in women, it then marketed its new disorders and drugs without regard for the basic science
of female sexual dysfunction.411
The pharmaceutical industry began with an attempt to redeﬁne women’s sexual problems. As discussed
earlier, the most widely used classiﬁcation of sexual dysfunctions has been the DSM-IV classiﬁcation system.
In 2000, a “consensus panel” of experts assembled to reassess this system and to propose new deﬁnitions.412
This meeting, however, was hardly a consensus panel: it was funded by pharmaceutical companies and
characterized by secrecy and cronyism. At the bottom of the consensus panel’s report, it is noted that the
panel was:
Supported by the Sexual Function Health Council of the American Foundation for
Urologic Disease through educational grants provided by Aﬃliated Research Cen-
ters, Eli Lilly/ICOS Pharmaceuticals, Pentech Pharmaceuticals, Pﬁzer Inc., Proctor
& Gamble, Schering-Plough, Solway Pharmaceuticals, TAP Pharmaceuticals and
Zonagen.413
Additionally, all 19 researchers present at the meeting were aﬃliated with and received funding from phar-
maceutical companies. Asterisks next to the researchers’ names indicated that they had:
410Ray Moynihan, The Making of a Disease: Female Sexual Dysfunction, 326 Brit. Med. J. 45, 45 (2006).
411Ray Moynihan, The Marketing of a Disease: Female Sexual Dysfunction, 330 Brit. Med. J. 192, 192 (2006).
412Basson et al., supra note 68, at 888.
66Financial interest and/or other relationship with Aﬃliated Research Centers, As-
tra, Bayer AG, Bristol-Myers Squibb, Eli Lilly, Fournier Group, Glaxo Well-
come, Lilly/ICOS, Matrix Pharma, NexMed, NitroMed, Pentech, Pﬁzer Inc., Pﬁzer
Canada Ltd., Pﬁzer UK, Pharmacia & Upjohn, Proctor & Gamble, Schering-
Plough, Senetek, Shwarz-Pharma, Solvay Pharmaceuticals, Syntec, Syntex, TAP
Pharmaceuticals, Vivus and/or Zonagen.414
Unlike a veritable consensus panel, this group worked in an atmosphere that was closed to the public; it did
not have formal scientiﬁc presentations; and it relied upon participation and support from pharmaceutical
industry employees.415 Unsurprisingly, the report it produced was declared “the work of a particular group
with serious conﬂicts of interest.”416
The substance of the panel’s report provides further evidence that the pharmaceutical industry was working
to create a disease so that it might develop treatments. As discussed earlier, the classiﬁcation system
the panel proposed was almost identical to the DSM-IV system.417 The central diﬀerence, as stated by
the panel, was that the newly proposed deﬁnitions were “based on physiological as well as psychological
pathophysiologies,” whereas the DSM-IV was purely a psychological model.418 Again, as noted earlier,
the DSM-IV is not exclusively a psychological model: it includes, for example, a category entitled “Sexual
Dysfunction Due to a General Medical Condition.”419 Rather than making any meaningful scientiﬁc changes
to the DSM-IV system, the consensus panel appeared to be working to shift female sexual dysfunction from
the psychological realm to the physiological realm. In Tiefer’s words, the panel wanted to “contribute to
an atmosphere that legitimizes female sexual dysfunction as a common condition with substantial organic
causes requiring treatment by urologists and new pharmaceutical products.”420 The panel worked to frame
female sexual dysfunction as a physiological disorder so that pharmaceutical companies could then provide
415Tiefer, supra note 134, at 228.
416Id.
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419American Psychiatric Association, supra note 67.
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67medications as treatment. By shifting perceptions about female sexual dysfunction, the panel created a
market for drugs.
The industry also worked to promote awareness of women’s sexual problems and treatment and, in doing
so, disregarded much relevant research and debate. As it developed Intrinsa, Proctor & Gamble targeted
health professionals, the media, and the public: it funded medical education activities, published a guide
on testosterone for reporters, and created a website.421 Additionally, P&G worked with public relations
companies and advertising ﬁrms to shape the public’s perceptions of female sexual dysfunction and its
treatment, setting aside an estimated $100 million for advertising.422 In its eﬀort to advertise female sexual
problems and testosterone, the pharmaceutical industry disregarded scientiﬁc disagreement and uncertainty
in the ﬁeld.423 The industry presented hypoactive sexual desire disorder as an accepted, uncontroversial
condition, for example, though numerous scholars believe calculating “normal” levels of desire downplays
the complexity of female sexual response and overlooks cultural and relational factors.424 The industry
also relied continuously on Laumann et al.’s ﬁgure that 43% of women suﬀer from sexual dysfunction.425
However, as was discussed earlier, this ﬁgure is inﬂated because it fails to consider women’s perceptions
of their so-called dysfunctions and whether they view them as such.426 In light of these facts, as well as
the industry’s role in reframing female sexual dysfunction as a physiological disorder, many scholars viewed
Intrinsa with suspicion.
The FDA’s Decision
The FDA’s failure to approve Intrinsa also set oﬀ a ﬂurry of criticism. Researchers accused the FDA of setting
unattainable safety standards, of failing to approve the drug for inappropriate reasons, and of discriminating
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68against women.
First, researchers asserted that the FDA’s demands for more safety data were unreasonable. Kingsberg, for
example, argued that the Advisory Committee’s safety requirements were both unrealistic and unclear.427 He
contended that committee member Dr. Nissen stated that P&G would need to conduct studies with 5,000-
10,000 more subjects—3.5 to 7 times as many subjects as in P&G’s original research, which P&G would be
unable to aﬀord—before the FDA’s safety concerns would be addressed.428 Numerous other suggestions were
made: some committee members suggested that studies in high-risk populations would be necessary, others
suggested animal studies to determine cardiovascular risk, and others proposed studies in premenopausal
women.429 As Kingsberg wrote, the FDA’s comments left researchers wondering what and “how much data
are suﬃcient to show that a new drug is ‘safe enough’?”430
In light of the FDA’s stringent demands for safety information, researchers also posited that its decision
was unduly inﬂuenced by recent developments in the drug industry as well as concerns about oﬀ-label use.
In particular, the FDA may have been inﬂuenced by the Women’s Health Initiative study, which found
that women taking estrogen-progesterone hormone replacement therapy had increased risks of breast cancer
and heart attacks in comparison to women on a placebo.431 The Committee may have been concerned
that testosterone, another sex steroid, might cause similar, unanticipated adverse events in women and thus
refused to approve the hormone without more safety information.432 Furthermore, it is possible that the
Vioxx debacle may have predisposed the FDA to reject Intrinsa: the increased cardiac risk associated with
Vioxx was not discovered until millions of patients had taken the drug, and the FDA may have wanted to
avoid another public health ﬁasco and publicity ﬁrestorm with Intrinsa.433
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69Still other experts have argued that the FDA refused to approve Intrinsa for fear of the consequences of its
oﬀ-label use. P&G studied Intrinsa’s eﬃcacy and safety in one group of women: women who had under-
gone hysterectomy and oophorectomy and were suﬀering from hypoactive sexual desire disorder. However,
premenopausal and naturally menopausal women also experience sexual dysfunction, and oﬀ-label use of
Intrinsa in these populations was likely.434 Indeed, as stated in P&G’s Intrinsa Brieﬁng Document, 114,000
prescriptions for testosterone products were written for women with sexual problems between 2000-2003.435
The FDA may have wanted to prevent Intrinsa use by women for whom the eﬃcacy and side eﬀects remained
unknown.
The FDA’s decision has also been critiqued as being decidedly anti-woman. This criticism has taken numerous
forms. Researchers have suggested that the FDA’s decision reﬂected an unwillingness to recognize hypoactive
sexual desire disorder as an important disorder and to acknowledge the signiﬁcance of women’s sexuality and
sexual concerns.436 One journalist, for example, cited the FDA’s decision to reject Intrinsa as an example of
the government’s suppression of female sexuality, while she noted, in contrast, that Medicaid has given free
Viagra to 198 sex criminals over the past 5 years.437 Similarly, it has been argued that the FDA imposed
diﬀerent standards on men and women: the Advisory Committee required more long-term safety data for
testosterone to be used in women despite the fact that there is no long-term safety data on the many uses
of testosterone replacement therapy in men.438
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70Final Thoughts
Our prior discussions of female sexual dysfunction and the relationship between testosterone and sexual dif-
ﬁculties inform our evaluation of Intrinsa, the medicalization of sexual dysfunction in women, and the FDA’s
decision. Though it is diﬃcult to decipher the precise motivations behind the pharmaceutical industry, the
consensus panel, and the FDA’s actions, we can conclude that testosterone is seldom the cause of sexual
dysfunction in women and is therefore rarely an appropriate treatment.
Female sexual dysfunction is not primarily a physiological disorder, as the pharmaceutical industry would
have the public believe. Rather, sexual problems in women can be psychosocial in origin and are often
the result of multiple factors. As discussed earlier, much sexual diﬃculty is rooted in psychological causes,
including fatigue and stress, inadequate information and ineﬀectual sexual techniques, and psychological
conﬂicts within the self.439 Additionally, it can be diﬃcult to locate one speciﬁc cause of a woman’s sexual
problems: for many women, their sexual concerns result from a constellation of interconnected variables.
For the most part, women’s sexual problems have been and continue to be viewed as predominantly psy-
chosocial in origin. Despite recent developments, the American Psychiatric Association’s framework, as
articulated in the DSM-IV, remains the dominant classiﬁcation of sexual dysfunctions. Additionally, the
deﬁnitions presented by the Working Group on A New View of Women’s Sexual Problems emphasize psy-
chosocial causes: sexual diﬃculties are thought to arise primarily out of inhibition and distress brought
about by cultural and relational factors.440 Even the consensus panel, which worked to shift female sex-
ual dysfunction from the psychosocial realm to the physiological realm, acknowledges that sexual problems
are based on “physiological as well as psychological pathophysiologies.”441 The best treatments for sexual
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71dysfunction target the underlying causes, and, given the numerous and complex reasons women suﬀer from
sexual problems, Intrinsa is not the panacea the pharmaceutical industry would have us believe it to be.
Even if we assume that physiological problems are to blame for most sexual diﬃculties, there is little ev-
idence for a causal relationship between low levels of testosterone and female sexual dysfunction. As we
have discussed, studies that ﬁnd an association between depressed testosterone levels and diminished libido
in normal (physically intact) women are plagued by small sample sizes and a lack of controls.442 If we
nonetheless overlook these methodological ﬂaws, we must remember that these studies show only an associ-
ation between depressed testosterone levels and depressed libido. It is not clear that low testosterone levels
caused the sexual dysfunction: it is possible that the reverse is true or that both were caused by some other
condition. The most methodologically rigorous and compelling study—Davis et al.—found no relationship
between testosterone levels and sexual problems in women.443 These data illuminate, at the very least, the
need for more research before we conclude that testosterone can cause as well as treat most women’s sexual
problems.
Additionally, were we to ﬁnd a convincing causal link between depressed testosterone levels and sexual dys-
function, women would have to exhibit low testosterone levels to create a general need for a drug like Intrinsa.
As we discussed, however, women rarely suﬀer from low levels of testosterone. Though researchers have long
believed aging and/or menopause to be associated with a decline in testosterone, the data do not support
this trend. Rather, the data suggest that testosterone levels do not change over time and, if they do decrease
for some middle-aged women, the decline is temporary. The women who appear to suﬀer from low levels of
testosterone are few. There is anecdotal evidence that women with hypothalamic-pituitary or adrenal con-
ditions, among others, may suﬀer from androgen insuﬃciency, though few studies have actually examined
androgen levels in these women. The most compelling evidence for reduced levels of testosterone is found
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72in studies of women who have undergone oophorectomy: ovary removal has been shown to be associated
with a 40-50% decline in circulating testosterone levels444 and, for some women, with a decline in sexual
functioning.445 Thus, taken together, the data on testosterone and sexual function indicate that there may
be a causal link between low levels of testosterone and sexual dysfunction only in women who have had their
ovaries removed. Testosterone supplements, like Intrinsa, are appropriate treatment for sexual problems in
these women alone.
With these thoughts in mind, we conclude that Intrinsa, and testosterone generally, is not the solution
for women’s sexual problems. Of course, Proctor & Gamble purportedly developed Intrinsa for surgically
menopausal women, a group that exhibits depressed testosterone levels. This population, however, is small—
approximately 300,000 women undergo oophorectomy each year446—and P&G likely anticipated that normal
women would use Intrinsa. (Certainly, its intended advertising budget of $100 million suggests that P&G was
planning on reaching out to women in general.447) Indeed, given how few women have undergone oophorec-
tomy, it is probable that the majority of women taking Intrinsa would have been physically intact, or normal,
women. Thus, as it considered Intrinsa, the FDA confronted potential widespread use of testosterone in pop-
ulations of women for whom the beneﬁts and the risks of the drug remain, at best, unknown. Testosterone is
neither the cause of nor the solution for most female sexual dysfunction, and the FDA exhibited appropriate
caution in demanding more eﬃcacy and safety data before approving its use in any population of women.
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